Physicians

Paul A. Knepper MD, PhD / Principal Investigator

Zibute G. Zaparackas, MD / Co-Investigator

Dr. Paul A. Knepper
Dr. Zibute G. Zaparackas

Dr. Paul A. Knepper, MD, PhD

Principal Investigator

Dr. Paul A. Knepper has dedicated his life and career to determining the disease process that causes vision loss and finding solutions. Dr. Knepper has researched and practiced Ophthalmology for more than 40 years in Chicago with a focus on Age-related Macular Degeneration and Glaucoma.

Dr. Knepper grew up in a family of doctors. His grandfather was a general practitioner and his father specialized in Ophthalmology.

Focused, dedicated, and determined, with a love of music, Dr Knepper never accepts “no” for an answer. Instead, he is relentless in his pursuit of a treatments eye diseases. His passion is to benefit humanity. He doesn’t want the next generation of aging patients to live in fear of losing their vision without treatment options.

Paul A Knepper MD, PhD, Ophthalmology Expert & Researcher

Chicago, IL

Current Positions

  • Professor of Ophthalmology (primary appointment) and Surgery (Neurosurgery) (secondary appointment), Northwestern University, Feinberg School of Medicine, Chicago, IL
  • Senior Research Scientist, University of Illinois at Chicago, Department of Ophthalmology and Visual Sciences, Chicago, IL
Research
  • Senior Research Scientist, 80 percent time commitment, University of Illinois at Chicago, Department of Ophthalmology and Visual Sciences, Chicago, IL
Clinical
  • Ophthalmologist, private practice, 20 percent time commitment, 150 East Huron, Suite 1000, Chicago, IL
Immunodiagnosis and Agricultural Strategy
  • CEO, Testog Inc, 150 East Huron Street, Suite 1000, Chicago, IL and 1200 Kingdom Road, Dixon, IL

Hospital Staff Appointments

  • Medical Attending, Northwestern Memorial Hospital, 1985 to present.
  • Associate Attending, Northwestern Memorial Hospital, 1978 to 1985.
  • Attending, The Children’s Memorial Hospital, 1978 to present.

Consultant

  • Rehabilitation Institute of Chicago, Chicago, IL, 1981 to present

Academic Degrees

  • B.A. – Northwestern University, History and Literature of Religion, 1964.
  • M.D. – Northwestern University Medical School, 1968.
  • F.A.O.O. – Fellow of American Academy of Ophthalmology and Otolaryngology, 1978.
  • Ph.D. – Northwestern University, Anatomy and Cell Biology, 1980.
  • FARVO – Fellow Association for Research in Vision and Ophthalmology, 2009; Gold medal in 2019.

Licensed to Practice Medicine in

  • State of Illinois, #36-43045, 1969
  • State of Missouri, #R-3617, 1969
  • State of Louisiana, #R-0352, 1974

Board Certified

  • National Board of Medical Examiners, 1969.
  • American Board of Ophthalmology, 1978.

Internship

  • Straight Medical, Cook County Hospital, Chicago, IL, 1968-1969.

Residency Training

  • Ophthalmology, Northwestern University Medical School, Chicago, IL, July 1970 to June 1973, Chairman:  David E. Shoch, M.D., Ph.D.

Postgraduate Training

  • Anatomy and Cell Biology, Northwestern University Graduate School, Chicago, IL, August 1976 to March 1980, Thesis Advisor:  Albert I. Farbman, Ph.D.; Ph.D. Thesis: Glycosaminoglycans and Aqueous Outflow Resistance.

Fellowships

  • Biochemistry Fellowship, Department of Biochemistry, Northwestern University, Chicago, IL, August 1969 to June 1970, Advisor: E. Albert Zeller, M.D., Ph.D.
  • Heed Fellow, Glaucoma Research Fellowship, Department of Anatomy, Northwestern University Medical School, Chicago, IL, July 1973 to June 1974, Advisor: William Bondareff, M.D., Ph.D.

Military Service

  • United States Army, Major, Chief of Ophthalmology, Fort Polk, LA, July 1974 to June 1976.

Honors and Awards

  • Heed Ophthalmic Fellowship, Research on Cellular Mechanisms in Glaucoma, 1973 to 1974.
  • Award of Meritorious Service, United States Army, 1976.
  • Northwestern University Fellowship, 1976 to 1979.
  • G.I. Bill for Postgraduate Studies, 1976 to 1980.
  • Scholars Award, Research to Prevent Blindness-Olga Keith Wiess Scholars Award, 1987.
  • ARVO Fellow, Silver Medal, 2009; Gold Medal, 2019.

Teaching Appointments

  • Associate, Department of Anatomy, Northwestern University Medical School, Chicago, IL, 1978 to 1980.
  • Associate, Department of Ophthalmology, Northwestern University Medical School, Chicago, IL, 1978 to 1980.
  • Assistant Professor, Department of Ophthalmology, Northwestern University Medical School, Chicago, IL, 1980 to 1983.
  • Assistant Professor, Department of Cell Biology and Anatomy, Northwestern University Medical School, Chicago, IL, 1980 to 1982.
  • Associate Professor, Department of Ophthalmology, Northwestern University Medical School, Chicago, IL, 1983 to 2019.
  • Associate Professor, Department of Surgery (Neurosurgery), Northwestern University Medical School, Chicago, IL, 1987 to 2019.
  • Professor, Department of Ophthalmology, Northwestern University Medical School, Chicago, IL, 2019 to present

National and Government Committees

  • Ad Hoc Member of National Eye Institute Study Section, National Institute of Health,1985 to present.
  • Grants-in-Aid Review Panel, National Society to Prevent Blindness, 1993 to 1997.

Membership in Societies

  • American Academy of Ophthalmology
  • Chicago Ophthalmology Society
  • American Association of Ophthalmology
  • American Society of Contemporary Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • International Congress for Eye Research
  • Trabecular Meshwork Society
  • American Medical Association
  • Illinois Medical Society
  • Cook County Medical Society
  • Society for Developmental Biology
  • New York Academy of Sciences
  • Society for Neuroscience
  • International Society for Eye Research
  • International Brain Research Organization

Editorial Appointments

  • Reviewer, Investigative Ophthalmology and Visual Science, 1982 to Present.
  • Reviewer, Experimental Eye Research, 1983 to Present.
  • Reviewer, Current Eye Research, 1984 to Present.
  • Reviewer, American Journal of Ophthalmology, 1987 to Present.
  • Reviewer, Neurosurgery, 1996 to Present.
  • Reviewer, Science, 1996 to Present.
  • Reviewer, Journal of Glaucoma, 1999 to Present
  • Reviewer, Genomics, 1999 to Present
  • Reviewer, Human Molecular Genetics, 2010 to Present
  • Reviewer, PlosOne, 2011 to Present

Research Grants

  1. National Institutes of Health, Grant No. RR 05370, Project Title: Trabecular Meshwork Glycosaminoglycans.  Principal Investigator: P.A. Knepper, M.D., Ph.D.  Funding Period:  10/1/80 to 9/30/81.  Direct costs, $4,840.
  2. Aileen S. Andrew Foundation, Project Title: Cell Mechanisms in Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  5/1/81 to 4/30/82.  Direct costs, $5,000.
  3. Illinois Society for Prevention of Blindness, Project Title: Steroid Induced Ocular Hypertension.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 6/1/81 to 5/31/82.  Direct costs, $1,920.
  4. National Institutes of Health, Grant No. EY 04175, Project Title: Steroid Effects on Trabecular Meshwork Glycosaminoglycans.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  9/1/81 to 8/31/84.  Direct costs to Northwestern University, Laboratory For Oculo-Cerebrospinal Investigation, $130,791; Indirect costs to Northwestern University, Children’s Memorial Hospital, $70,606.
  5. Spina Bifida Association of Atlanta, Project Title: Myelomeningocele Research. Principal Investigator:  D.G. McLone, M.D., Ph.D.; Co-Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  9/1/81 to 8/30/84.  Direct costs, $59,700.
  6. Illinois-Eastern Iowa District of Kiwanis International, Project Title: Myelomeningocele Research.  Principal Investigator:  D.G. McLone, M.D.; Ph.D.: Co-Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  5/1/82 to 4/30/90.  Direct costs, $177,500.
  7. Aileen S. Andrew Foundation, Project Title: Glaucoma Research.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/1/82 to 5/31/83.  Direct costs, $60,000 for purchase of High Performance Liquid Chromatograph.
  8. Dr. Scholl Foundation, Project Title: Spina Bifida Research.  Principal Investigator: D.G. McLone, M.D., Ph.D.; Co-Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  11/1/82 to 10/31/83.  Direct costs, $30,000.
  9. Aileen S. Andrew Foundation, Project Title: Cell Surface of Glaucoma Cells.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/1/83 to 5/31/84.  Direct costs, $66,000 for purchase of a Computer-controlled Scanning Microspectrophotometer.
  10. Children’s Memorial Research Foundation, Project Title: Glycoconjugates and Morphogenesis.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 9/1/83 to 8/31/85.  Direct Costs, $40,900.
  11. Aileen S. Andrew Foundation, Project Title: Glaucoma Research.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  12/1/84 to 5/1/85.  Direct costs, $50,000.
  12. National Eye Care Foundation, Project Title: Biochemical Studies on the Etiology of Congenital Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  7/1/84 to 6/30/85.  Direct costs, $5,000.
  13. A.C. Buehler Foundation, Project Title: Microscope Research Facility.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  1/1/85 to 1/1/87.  Equipment for the Core Research Microscope Facility, Children’s Memorial Research Foundation. Direct costs $740,191.
  14. Alcon Laboratories, Inc., Project Title: Primate Model of Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  2/1/86 to 7/31/86.  Direct costs, $40,000.
  15. National Institutes of Health, Grant No. EY 06662, Project Title: The Extracellular Matrix in Glaucoma.  Program Director:  Paul F. Palmberg, M.D., Ph.D., University of Miami School of Medicine; Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  7/1/86 to 6/30/89.  Direct costs to Northwestern University, Laboratory for Oculo-Cerebrospinal Investigation, $177,695; Indirect costs to Northwestern University, Children’s Memorial Hospital, $97,732.
  16. Alcon Laboratories, Inc., Project Title: Research in Glaucoma.  Principal Investigator: P.A. Knepper, M.D., Ph.D.  Funding Period:  5/1/87 to 12/31/87.  Direct costs, $40,000.
  17. Research To Prevent Blindness, Project Title: Research in Ophthalmology, Olga Keith Wiess Scholars Award:  P.A. Knepper, M.D., Ph.D.  Funding Period:  7/1/87 to 6/30/88. Direct costs, $30,000.
  18. Alcon Laboratories, Inc., Project Title: Research in Glaucoma.  Principal Investigator: P.A. Knepper, M.D., Ph.D.  Funding Period: 7/1/88 to 6/30/90.  Direct costs, $115,360.
  19. National Children’s Eye Care Foundation, Project Title: Biochemical Studies of Congenital Glaucoma.  Principal Investigator: P.A. Knepper, M.D., Ph.D.  Funding Period: 9/l/89 to 8/31/90.  Direct costs, $5,000.
  20. The Glaucoma Foundation, Project Title: Glaucoma Research.  Principal Investigator: P.A. Knepper, M.D., Ph.D.  Funding Period:  1/1/90 to 12/31/90.  Direct costs, $8,000.
  21. Illinois-Eastern Iowa District of Kiwanis International, Project Title: Myelomeningocele Research.  Principal Investigator:  D.G. McLone, M.D.; Ph.D.; Co-Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  8/1/90 to 7/31/94.  Direct costs, $100,000.
  22. Alcon Laboratories, Inc., Project Title: Efficacy of IOP-lowering Compounds in Corticosteroid Induced Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D. Funding Period:  10/1/90 to 9/30/91.  Direct costs, $40,000.
  23. National Children’s Eye Care Foundation, Project Title: Morphological Studies of the Cause of Congenital Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D. Funding Period:  9/1/91 to 8/30/92.  Direct costs, $4,153.
  24. Alcon Laboratories, Inc., Project Title: Efficacy of IOP-lowering Compounds in Corticosteroid Induced Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D. Funding Period:  1/1/92 to 12/31/92.  Direct costs, $60,000.
  25. Illinois Society for the Prevention of Blindness, Project Title: Hyaluronic Acid Isoforms in Aging and in Primary Open-Angle Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  7/1/92 to 6/30/93.  Direct costs, $3,900.
  26. The Glaucoma Foundation, Project Title: Surface Tension of Hyaluronic Acid in Aging and in Primary Open-angle Glaucoma.  Principal Investigator: P.A. Knepper, M.D., Ph.D.  Funding Period: 7/21/92 to 6/30/93.  Direct Costs, $5,000.
  27. The Glaucoma Foundation, Project Title: Cell Biology of Open-Angle Glaucomas. Principal Investigator: P.A. Knepper, M.D., Ph.D.  Funding Period:  7/1/93 to 6/30/95. Direct Costs, $20,000.
  28. Illinois-Eastern Iowa District of Kiwanis International, Project Title: Myelomeningocele research.  Principal Investigator:  D.G. McLone, M.D. Ph.D.; Co-Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  8/1/94 to 7/31/98.  Direct Costs, $100,000.
  29. American Health Assistance Foundation, Project Title: On the Role of Hhyaluronan in Aging and PrimaryOpen angle Glaucoma.  Principal Investigator:  P.A. Knepper, MD, PhD.  Funding Period: 4/1/95 to 3/31/97.   Direct Costs, $50,000.
  30. Northwestern University Medical School, Intramural Research Grant, Project Title: Candidate Pax3 Gene amd Myelomeningocele.  Principal Investigator:  P.A. Knepper, MD, PhD.;  Co-Investigator:  D.G. McLone, MD, PhD.  Funding Period: 4/1/95 to 3/31/96.  Direct costs: $13,500.
  31. Northwestern University Medical School, Intramural Research Grant, Project Title: Extracellular Matrix in Glaucoma.  Principal Investigator:  P.A. Knepper, MD, PhD. Funding Period: 6/1/97 to 5/31/98.  Direct costs: $20,000.
  32. National Institutes of Health, Project Title: Extracellular Matrix in Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period:  5/1/00 to 4/30/04.  Direct costs to Northwestern University, Laboratory for Oculo-Cerebrospinal Investigation, $416,413; Indirect costs to Northwestern University, Children’s Memorial Hospital, $178,382.  Total $594,795.
  33. Midwest Eyebank Tissue Culture Scientific Research Award, Project Title: A New Theory on the Cause of Primary Open-Angle Glaucoma.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 5/1/03 to 4/30/05.  Direct costs: $15,000.
  34. Illinois Society for the Prevention of Blindness, Project Title: On the Biological Basis of Increased Severity of Glaucoma in African Americans. Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 5/1/03 to 4/30/05.  Direct costs: $5,000.
  35. Illinois Society for the Prevention of Blindness, Project Title: CD44 and Macular Degeneration. Principal Investigator:  P.A. Knepper, MD, PhD.  Funding Period: 5/1/05 to 4/30/06.  Direct costs: $5,000.
  36. Alcon Laboratories, Inc., Project Title: sCD44 and Primary Open-Angle Glaucoma. Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 4/1/06 to 12/31/06. Direct costs: $20,000.
  37. Illinois Society for the Prevention of Blindness, Project Title: Biomarker discovery using hypo-phosphorylated sCD44 as a new diagnostic test for Primary Open-Angle Glaucoma.  Principal Investigator:  P.A. Knepper, MD, PhD.  Funding Period: 5/1/06 to 4/30/07.  Direct costs, $5,000.
  38. Alcon Laboratories, Inc., Project Title: On the cause, treatment and prevention of Primary Open-Angle Glaucoma and Alzheimer’s Disease.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.; Co-investigator, Michael J. Nolan, Funding Period: 1/1/07 to 12/31/08.  Direct costs, $50,000.
  39. Alcon Laboratories, Inc., Project Title: On the cause, treatment and prevention of Primary Open-Angle Glaucoma and Alzheimer’s Disease.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.;  Co-investigator, Michael J. Nolan, Funding Period: 1/1/08 to 12/31/08.  Direct costs, $100,000.
  40. Alcon Laboratories, Inc., Project Title: On the cause, treatment and prevention of Primary Open-Angle Glaucoma and Alzheimer’s Disease.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 4/1/09 to 12/31/09.  Direct costs, $75,000.
  41. Alcon Laboratories, Inc., Project Title: On the cause, treatment and prevention of Primary Open-Angle Glaucoma and Alzheimer’s Disease.  Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 1/1/10 to 5/1/11.  Direct costs, $100,000.
  42. Bright Focus Foundation: Activation of innate immune Toll-4 receptor in POAG.   Principal Investigator:  P.A. Knepper, M.D., Ph.D.  Funding Period: 5/1/11 to 4/30/14.  Direct costs, $100,000.00.
  43. Illinois Society for Prevention of Blindness, Project Title: New theory for the cause of POAG.  Principal Investigator: E. Martin M.D., Mentor  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/1/16 to 5/31/18.  Direct costs, $4950, funded
  44. Testog Immunodiagnositics. On the cause and prevention of primary open angle glaucoma and Alzheimer’s disease. Principal Investigator:  P.A.Knepper, M.D., Ph.D. Funding Period: 8/1/16 to 7/31/21. Direct costs, $100,000.
  45. Illinois Society for Prevention of Blindness, Project Title: Curcumin  as a biomarker an treatment for age-related macular degeneration. Principal Investigator: L.Dasso, MS,  Mentor  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/1/18 to 5/31/19.  Direct costs, $3700, funded
  46. Illinois Society for Prevention of Blindness, Project Title: The role of plasmalemma vesicle-associated protein in angiogenesis and the effect of curcumin in age-related macular degeneration.  Principal Investigator: A Pastapur BA, Mentor:  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/1/20  to 5/31/21.  Direct costs, $4915.

Training Grants

  1. National Institute of Health, Medical Student Short-Term Research Training Grant, No. 00015 T35/81, Project Title:  Glycoconjugates and Cerebrospinal Fluid Outflow. Predoctoral Trainee:  Ralph E. Losey, Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding Period:  9/28/81 to 12/27/81.  Direct costs, $1,670.
  2. National Institute of Health, Medical Student Short-term Research Training Grant, No. 00031, T35/82, Project Title:  Neural Crest Cell Migration and Congenital Glaucoma. Predoctoral Trainee:  Peter Sakol, Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/26/82 to 9/25/82.  Direct costs, $1,670.
  3. National Institutes of Health, Visual Research Training Grant, Project Title: Visual Physiology and Chemistry.  Program Directors:  Sanford E. Ostroy, Ph.D., Purdue University, and Lee Jampol, M.D., Northwestern University.  Postdoctoral Trainee: Russell G. Higbee, Ph.D., Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding Period: 8/1/85 to 7/31/90.  Direct costs, $30,000.
  4. Baxter Student Research Award, Northwestern University Medical School, Project Title: The Role of Carbohydrates in the Histogenesis and Cerebellar Development of Abnormal and Normal Mice.  Predoctoral Trainee:  Grant Sinson, Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/14/86 to 9/14/86.  Direct costs, $1,500.
  5. Baxter Student Research Award, Northwestern University Medical School, Project Title: Studies on Genetic and Metabolic Induced Neural Tube Defects.  Predoctoral Trainee: Ted Johnson, Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding period:  6/08/87 to 9/28/87.  Direct costs, $1,500.
  6. Fight For Sight, Inc., Project Title: The Extracellular Matrix of the Trabecular Meshwork and Growth Factors and Their Relationship to Primary Open-Angle Glaucoma.  Postdoctoral Fellow:  Bryan S. Sires, Ph.D., Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding period:  7/1/87 to 10/1/87.  Direct costs, $3,000.
  7. Ann Stromberg Award, Northwestern University Medical School, Project Title: Glycoconjugates and Glaucoma.  Predoctoral Trainee:  Jodi Abramson, Preceptor:  P. A. Knepper, M.D., Ph.D.  Funding Period:  9/1/89 to 12/15/89.  Direct costs, $1,000.
  8. Baxter Student Research Award, Northwestern University Medical School, Project Title: Arachnoid in Cell Culture:  Influence of Substratum on Differentiation.  Predoctoral Trainee:  Jennie U. Sung, Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding Period:  6/l/90 to 9/l/90.  Direct costs, $l,500.
  9. Medical Student Research Award, Northwestern University Medical School, Project Title: Desmoplakin I and Thy-1 in Monkey and Mouse Brain and Eye.  Predoctoral Trainee:  Jennie U. Sung, Preceptor:  P.A. Knepper, M.D., Ph.D.  Funding Period: 1/28/91 to 4/5/91.  Direct costs, $3,000.
  10. Medical Student Research Award, Northwestern University Medical School, Project Title:  The identification of hyaluronic acid binding proteins in abnormal and normal samples of cerebrospinal fluid.  Predoctoral Trainee:  Kimberly A. Skelding, Preceptor: P.A. Knepper, M.D., Ph.D.  Funding Period: 6/1/93 to 9/1/93.  Direct costs, $2,500.
  11. Alpha Omega Alpha Award, Project Title: Hindbrain Malformations Induced by pressure-regulated Manipulation of Gycosaminoglycans in the Mesencephalic Vesicle of Chick Embryos.  Predoctoral Trainee: Ty J. Gluckman, Preceptor: P.A. Knepper, M.D., Ph.D.  Funding Period: 6/1/94 to 10/1/94.  Direct cost, $3,500.

Mentoring in the Laboratory for Oculo-Cerebrospinal Investigation (LOCI) to guide, influence and assist students into medicine.

  1. Pre-medical students (33) who initially were not admitted to medical school; 28 have been accepted; four in process and one lost to follow up. Medical school acceptance rate 85%.
  2. Medical students (6) all were accepted into residency programs: Three in ophthalmology residency.
  3. Pre-doctoral (2); all completed their PhD degrees.
  4. Post-doctoral students (3).
  5. Fellows (5).

Articles

  1. Hsu M, Knepper PA, Shoch D, Zeller EA. On the effects of reserpine and the benzoquinolizine RO 4-1284 on the tonographic parameters of the rabbit eye. Invest Ophthalmol Vis Sci. 9:551-552, 1970.
  2. Zeller EA, Shoch D, Czerner EB, Hsu MY, Knepper PA. Enzymology of the refactory media of the eye. X. Effects of topically administered bradykinin, amine releasers, and pargyline on aqueous humor dynamics.  Invest Ophthalmol Vis Sci. 10:274-281, 1971.
  3. Knepper PA, Chalkley T. New corneal transplant scissors.  Am J Ophthalmol. 75:896-897, 1973.
  4. Choromokos E, Knepper PA. Fundus photography without mydriatics.  Am J Ophthalmol. 75:1008-1009, 1973.
  5. Zeller EA, Knepper PA, Shoch D. Differential effects of inhibitors of monoamine oxidase types A and B on the adrenergic system of the rabbit iris.  Invest Ophthalmol Vis Sci.14:155-159, 1975.
  6. Knepper PA, Farbman AI, Bondareff W. A smooth muscle plexus associated with the aqueous outflow pathway of the rabbit eye.  Anat Rec. 182:41-51, 1975.
  7. Knepper PA, Breen M, Weinstein HG, Blacik LJ. Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: Effect of age and dexamethasone.  Exp Eye Res. 27:567-575, 1978.
  8. Breen M, Vitello LB, Weinstein HG, Knepper PA. Keratan sulfate-like substance as a function of age in the brain and eye.  In Gregory JD and Jeanloz RW (Eds): Glycoconjugate Research, Vol 1.  New York:  Academic Press, 1979, pp 511-514.
  9. Knepper PA. Glycosaminoglycans and aqueous outflow resistance.  Ph.D. Thesis, Northwestern University.  Ann Arbor, MI:  University Microfilms International, 1980.
  10. Knepper PA, Farbman AI, Telser AG. Aqueous outflow pathway glycosaminoglycans. Exp Eye Res. 32:265-277, 1981.
  11. Breen M, Weinstein HG, Knepper PA, Blacik LJ, Lewandowski DG, Baltrus BM. Cerebral cortex glycosaminoglycans as a function of age in the Fischer-344 and King (Sprague-Dawley) Cesarean-derived, barrier-raised rats.  Age. 4:71-77, 1981.
  12. Breen M, Weinstein HG, Knepper PA, Blacik LJ, Lewandowski DG, Baltrus BM. Cerebellar glycosaminoglycans as a function of age in Fischer-344 and King (Sprague-Dawley) Cesarean-derived barrier raised rats.  Age. 4:79-84, 1981.
  13. Breen M, Knepper PA, Weinstein HG, Blacik LJ, Lewandowski DG, Baltrus BM. Microanalysis of glycosaminoglycans.  Anal Biochem. 113:416-422, 1981.
  14. Weinstein HG, Blacik LJ, Breen M, Knepper PA.  The presence of a keratan sulfate-like glycoconjugate in microsomes of the cerebral cortex.  Biochem Biophys Res Commun. 111(1):28-35, 1983.
  15. McLone DG, Suwa J, Collins JA, Poznanski S, Knepper PA. Neurulation: Biochemical and morphological studies on primary and secondary neural tube defects.  In the American Society for Pediatric Neurosurgery (Ed):  Concepts in Pediatric Neurosurgery, Vol 4.  Basel:  S Karger, 1983, pp 15-29.
  16. Knepper PA, Losey RK, Collins JA, McLone DG, Weinstein HG, Breen M. Age-related changes in the cerebrospinal fluid outflow glycosaminoglycans.  Neurobiol Aging 4:163-168, 1983.
  17. Knepper PA, Collins JA, Weinstein HG, Breen M. Aqueous outflow pathway complex carbohydrate synthesis in vitro.  Invest Ophthalmol Vis Sci. 24:1546-1551, 1983.
  18. Breen M, Weinstein HG, Knepper PA. Synaptosomes and synaptic membranes: Isolation and morphology.  In Reid E, Cook GMW, and Morre DJ (Eds):  Investigation of Membrane-Located Receptors, Vol 13.  New York: Plenum Press, 1984, pp 243-244.
  19. Knepper PA, Farbman AI, Telser AG. Exogenous hyaluronidases and degradation of hyaluronic acid in the rabbit eye.  Invest Ophthalmol Vis Sci. 25:286-293, 1984.
  20. Beauchamp GR, Knepper PA. Role of the neural crest in anterior segment development and disease.  J Pediatr Ophthalmol Strabismus. 21:209-214, 1984.
  21. Beauchamp GR, Lubeck D, Knepper PA. Glycoconjugates, cellular differentiation and congenital glaucoma.  J Pediatr Ophthalmol Strabismus. 22:149-155, 1985.
  22. Breen M, Weinstein HG, Blacik LJ, Knepper PA. Matrix template for computer presentation of serial dilution titer data: Membrane/lectin interactions.  Biochem Arch. 1:31-36, 1985.
  23. Knepper PA, Collins JA, Frederick R. Effect of dexamethasone, progesterone, and testosterone on IOP and GAGs in the rabbit eye.  Invest Ophthalmol Vis Sci. 26:1093-1100, 1985.
  24. Caldarelli M, McLone DG, Collins JA, Suwa J, Knepper PA.: Vitamin A induced neural tube defects in the mouse.  In: Chapmen PH (Ed):  Concepts in Pediatric Neurosurgery, Vol 6.  Basel:  S Karger, 1985, pp 161-171.
  25. McLone DG, Knepper PA. Role of complex carbohydrates and neurulation.  Pediatr Neurosci. 12:2-9, 1986.
  26. Knepper PA. Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension.  U.S. Patent #4,617,299, October 14, 1986.
  27. Vanden Hoek TL, Goossens W, Knepper PA. Fluorescence-labeled lectins, glycoconjugates, and the development of the mouse AOP.  Invest Ophthalmol Vis Sci. 28:451-458, 1987.
  28. Knepper PA. Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension.  WO19878802628, 1987.
  29. Knepper PA, McLone DG. Glycosaminoglycans and the outflow pathways of the eye and brain.  Pediatr Neurosci. 12:240-251, 1986/1987.
  30. McLone DG, Herman J, Higbee RG, Goossens W, Knepper PA. Glycoconjugates and the development of the cerebrospinal fluid outflow pathway in the mouse.  In:  Marlin AE (Ed):  Concepts in Pediatric Neurosurgery, Vol 8.  Basel:  S Karger, pp 97-110, 1988.
  31. Ersahin Y, Higbee RG, Vanden Hoek T, McLone DG, Knepper PA. Vitamin A-induced suppression/enhancement of protein glycosylation and neurulation.  Pediatr Neurosci. 13:293-303, 1988.
  32. McLone DG, Knepper PA. The cause of Chiari II malformation:  A unified theory. Pediatr Neurosci. 15:1-12, 1989.
  33. Knepper, PA. Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension.  U.S. Patent #4,812,448, March 14, 1989.
  34. McLone DG, Nakahara S, Knepper PA. The Chiari II Malformation: Pathogenesis and Dynamics. In:Marlin AE (Ed): Concepts in Pediatric Neurosurgery, Vol. 11,1-17,1991.
  35. Knepper PA, McLone DG, Goossens W, Vanden Hoek T, Higbee RG.  Ultrastructural alterations in the aqueous outflow pathway of buphthalmic rabbits.  Exp Eye Res. 52:525-533, 1991.
  36. Knepper PA, McLone DG. Development of the spinal cord: Normal and abnormal neurulation.  In:  Park TS (Ed):  Spinal Dysraphism.  Cambridge:  Blackwell Scientific Publications Inc., pp 1-19, 1992.
  37. Higbee RG, Knepper PA. The use of ethanol for preserving proteins and glycoproteins of the trabecular meshwork.  J Glaucoma, 2:25-29, 1993.
  38. Gum GG, Knepper PA, Gelatt KN. Histochemical localization of glycosaminoglycans in the aqueous outflow pathways in normal beagle and beagles with inherited glaucoma, Prog Vet Comp Ophthalmol. 3:52-57, 1993.
  39. Mayanil CSK, Knepper PA. Synaptic vesicle and synaptic membrane glycoproteins during pre- and postnatal development of mouse cerebral cortex, cerebellum and spinal cord.  Dev Neurosci. 15:133-145, 1993.
  40. Johnson DH, Knepper PA. Microscale analysis of the glycosaminoglycans of human trabecular meshwork: A study in perfusion organ cultured eyes. J Glaucoma. 3:58-69, 1994.
  41. McLone DG, Dias MS, Goossens W, Knepper PA. Is myelomeningocele a progressive intrauterine disease? Pediatric Neuroscience.  15:133-145, 1994.
  42. Knepper PA, Covici S, Fadel JR, Mayanil CSK, Ritch R. Surface tension properties of hyaluronic acid.  J Glaucoma. 4:194-199, 1995.
  43. Knepper PA, Goossens W, Hvizd M, Palmberg PF. Glycosaminoglycan profile of the human trabecular meshwork in primary open-angle glaucoma.  Invest Ophthalmol Vis Sci. 37:1360-1367, 1996.
  44. Knepper PA, Goossens W, Palmberg PF. GAG stratification in normal and primary open-angle glaucoma JCT.   Invest Ophthalmol Vis Sci. 37:2414-2425,1996.
  45. Inagaki T, Wang KC, Higbee RG, McLone DG, Knepper PA. Concanavalin-A-induced open neural tube defects in chick embryos. Neuro Med-Chir. 36:691-696, 1996.
  46. McLone DG, Dias MS, Goossens W, Knepper PA. Pathological changes in exposed neural tissue of fetal delayed splotch (Spd) mice.  Childs Nervous System. 13:1-7, 1997.
  47. Knepper PA: Trabecular meshwork studies offer clues.: Cell, molecular biology approaches may aid understanding. Ophthalmology Times. 22(16):12, 1997.
  48. Knepper PA, Goossens WG, McLone DG. Ultrastructural studies of primary congenital glaucoma in rabbits. J Ped Ophthalmol Strab, 34:365-371. 1997.
  49. Wang KC, Higbee R, Knepper PA, McLone DG. Functional opening of the fourth ventricular outlet in C57BL/6J and delayed splotch mouse embryos.  Pediatr Neurosurg, 27:176-181. 1997.
  50. Nye JS, Balkin N, Lucas H, Knepper PA, McLone, DG, Charrow J. Meningomyelocele and Waardenburg syndrome (type 3) in patients with interstitial deletions of 2q35 and the PAX3 gene:  Possible digenic inheritance of a neural tube defect.  Am J Med Gen. 75:401-408, 1998.
  51. Knepper PA, Mayanil CSK, Goossens W, McLone DG, Hayes E. The presence of transcription factors in fetal bovine sera.  In Vitro Cell Dev Biol – Animal.  34:170-174, 1998.
  52. Knepper PA, Goossens W, Mayanil CSK. CD44 localization in primary open-angle glaucoma.  Invest Ophthalmol Vis Sci. 39:673-680, 1998.
  53. Knepper PA, Mayanil CSK, Hayes E, Goossens W, Byrne RW, McLone DG.. The presence of transcription in chicken albumin, yolk and blastoderm.  In Vitro Cell Dev Biol. 35:357-363, 1999.
  54. Pang I-H, Moll H, McLaughlin MA, Knepper PA, DeSantis L, Epstein DL, Clark A.: Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A.  Exp Eye Research. 73:815-25, 2001.
  55. Knepper PA, Mayanil CSK, Goossens W, Wertz RD, Holgren C, Ritch R, Allingham RR. Aqueous humor in primary open-angle glaucoma contains an increased level of CD44S. Invest Ophthalmol Vis Sci. 343:133-139, 2002.
  56. Choi J, Miller AM, Nolan NJ,Yue BYJT, Thotz ST, Clark AF, Agarwal N, Knepper, PA. sCD44 is cytotoxic to trabecular meshwork and retinal ganglion cells in vitro.  Invest Ophthalmol Vis Sci. 46:214-22, 2005.
  57. Knepper PA, Fadel JR, Miller AM, Gossens W, Choi J, Nolan MJ, Whitmer S. Reconstitution of trabecular meshwork GAGs: Influence of hyaluronic acid and chondroitin sulfate on flow rates. Journal of Glaucoma.14:230-238, 2005.
  58. Knepper PA, Miller AM, Choi J, Wertz RD, Nolan MJ, Gossens W, Whitmer S, Yue BYJT, Ritch R, Liebmann JM, Allingham RR, Samples JR. Hypo-phosphorylation of aqueous humor sCD44 and primary open-angle glaucoma.   Invest Ophthalmol Vis Sci.46:2829-2837, 2005.
  59. Knepper PA, Nolan MJ, Yue  BYJT, Samples JR, Knepper PA. Letter to the Editor regarding Hypo-phosphorylation of aqueous humor sCD44 and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2006.
  60. Fautsch M, Johnson DH, Acott TS, Aihara M,  Bhattacharya SK, Borrás T, Camras CB, Civan M, Clark AF, Crosson CF, Crowston JG,  Epstein D, Ethier CR,  Freddo TF, Gong H,  Gonzalez P,  John SW,  Johnson M, Kaufman PL, Knepper PA, Lindsey J,  Lütjen-Drecoll E,  Peters DM, Rao PV, Roy S, Russell P, Stamer D, Tamm ER,  Toris CB, Weinreb RN, Yue B. The Second ARVO Pfizer Research Institute Working Group. Aqueous humor outflow: What do we know? Where will it lead us? Invest          Ophthalmol Vis Sci.47: 4181-4187, 2006.
  61. Miller, AM, Nolan MJ, Choi J, Koga T, Shen X, Yue BYJT, Knepper PA.  Lactate treatment causes NK-κB activation and CD44 shedding in cultured trabecular meshwork cells.  Invest Ophthalmol Vis Sci. 48:1615-1621, 2007.
  62. Nolan MJ, Giovingo MC, Miller AM, Wertz RD, Ritch, R, Liebmann JM, Allingham RR, Herndon LW, Wax, MB, Smolyak R, Hasan F, Barnett EM, Samples JR, Knepper PA.  Influence of race on visual field loss and aqueous humor soluble CD44 concentration in primary open-angle glaucoma. J Glaucoma. 16:419-429, 2007.
  63. Knepper PA, Yue BYJT.  Abnormal trabecular meshwork outflow pathway.  In: Levin LA, Albert DM (eds): Ocular Disease: Mechanisms and Management. London UK, Elsevier, 2010. (pp171-177).
  64. Knepper PA, Nolan MJ, Yue BYJT. CD44 and Primary Open Angle Glaucoma. In: Schacknow PN, Samples JR (eds): The Glaucoma Book. London UK, Elsevier, 2010, pp 939-952.
  65. Knepper PA, Nolan MJ, Yue BYJT. How the revolution in cell biology will affect glaucoma: Biomarkers. In: Schacknow PN, Samples JR (eds): The Glaucoma Book. London UK, Elsevier, 2010 pp 933-938.
  66. Belforte N, Sande P, de Zavala N, Knepper PA, Rosenstein RE. Effect of chondroitin sulfate on intraocular pressure in rats.  Invest Ophthalmol Vis Sci. 51:5768-75, 2010.
  67. Knepper PA, Samples JR, Yue, BYJT. Biomarkers of primary open-angle glaucoma. Exp Review Ophthalmology. 5 731-742, 2010.
  68. Nolan MJ, Koga T, Walker L, McCarty R, Grybauskas A, Giovingo MC, Skuran KJ, Kuprys PV,  Knepper PA.  sCD44 internalization in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 54:592-601, 2013.
  69. Knepper PA, Grybauskas A, Kuprys P, Skuran K, Samples JR. Biomarkers to predict glaucoma surgical success In: Samples JR and Ahmed J (eds): Surgical Innovations in Glaucoma. New York, 2014 pp.287-294.
  70. Giovingo MC, Nolan M, McCarty R, Pang I-H, Clark AF, Beverly RM, Schwartz S, Stamer WD, Walker L, Grybauskas A, Skuran K, Kuprys P, Yue BYJT, Knepper PA. sCD44 overexpress increased intraocular pressure in vivo and increases outflow                                 resistance in vitro.  Molecular Vision.  19:2151-2164, 2014.
  71. Grybauskas A, Koga T, Kuprys PV, Nolan M, McCarty R, Walker L, Yue BYJT, Knepper PA.  ABCB1 transporter and innate immune Toll-like 4 receptor interaction in trabecular meshwork cells.  Molecular Vision. 21:201-212, 2015.
  72. Green KA, Knepper PA. Biomarkers in primary open-angle glaucoma. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2016 to 2018 pp 173-184.  Kugler, Amsterdam.
  73. Green KA, Giovingo M, Knepper PA. Optic nerve blood flow in primary open-angle glaucoma.In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2016 to 2018. Kugler, Amsterdam.
  74. Green KA, Volpe N, Knepper PA. Cerebrospinal fluid dynamics and primary open-angle glaucoma. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2016 to 2018. Kugler, Amsterdam.
  75. Knepper PA, Norkett WM, Green KA, Wanderling C, Kuprys PV, Giovingo M, Tanna AP, Pasquale LR. Microvascular disease in glaucoma. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2016 to 2018.  Kugler, Amsterdam.
  76. Green KA, Yue BYJT, Samples JR, Knepper PA. Trabecular meshwork cell death in primary open-angle glaucoma. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2016 to 2018. Kugler, Amsterdam.
  77. Knepper PA, Green KA, Samples JR. The multiple hit theory on the pathogenesis of primary open-angle glaucoma.  In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2016 to 2018.  Kugler, Amsterdam.
  78. Samples JR, Knepper PA. The fibroblast and glaucoma surgery. In: Francis BA, Sarkisians S, Tan J (eds): Minimally invasive glaucoma surgery: The science and practice. New York, Thieme, 2017.
  79. Knepper, PA: Composition and method for inhibiting platelet aggregation. International Patent Application. WO2017/031300A1, 2017.
  80. Cousins CC, Kang JH, Bovee C, Wang J, Greenstein SH, Turalba A, Shen LQ, Brauner S, Boumenna T, Blum S, Levkovitch-Verbin H, Ritch R, Wiggs JL, Knepper PA, Pasquale LR. Nailfold capillary morphology in exfoliation syndrome. Eye (Lond) 31:698-707, 2017.
  81. Knepper, PA: Composition and method for inhibiting platelet aggregation. U.S. Patent 62/207/535, 2018.
  82. Keller KE, Bhattacharya SK, Borrás T,Brunner TM, Chansangpetch S, Clark AF, Dismuke WM, Du Y, Elliott MH, Ethier CR, Faralli JA,  Freddo TF, Fuchshofer R, Giovingo  M, Gong H, Gonzalez  P, Huang A, Johnstone MA, Kaufman PL, Kelley MJ, Knepper  PA, Kopczynski  CC, Kuchtey JG,  Kuchtey RW, Kuehn MH, Lieberman RL, Lin SC, Liton P,  Liu Y, Lütjen-Drecoll  E, Mao W, Masis-Solano  M, McDonnell F, McDowell CM, Overby DR,  Pattabiraman PP,  Raghunathan VK, Rao PV, Rhee DJ, Chowdhury UR, Russell  P, Samples JR, Schwartz D,  Stubb EB, Tamm ER,  Tan JC,  Toris CB,  Torrejon  KY, Vranka  JA, Wirtz MK, Yorio T, Zhang  J, Zode GS,  Fautsch MP, Peters DN , Acott TS,  Stamer WD. Consensus recommendations for trabecular meshwork cell isolation, characterization and culture. Exp Eye Res. 171:164-173, 2018.
  83. Pfahler NM, Bielskus I, Miazga M, Kaufman E, Mandich M, Knepper PA. Innate Immune System in Primary Open Angle Glaucoma. . In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2018 to 2020, In Press.  Kugler, Amsterdam.
  84. Pfahler NM, Miazga M, Bielskus I,Kaufman E, McGuire J, Cronin T, McCarty R, Giovingo M, Volpe N, Tanna AP,  Knepper PA. Systemic manifestations of microvascular disease in primary open angle glaucoma.  In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2018 to 2020 pp147-163. Kugler, Amsterdam.
  85. Knepper PA, Pfahler NM, McGuire J, Bielskus I, Giovingo M, Volpe NM. The link between primary open angle glaucoma and Alzheimer’s disease. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2018 to 2020 pp171-185.  Kugler, Amsterdam.
  86. Cousins CC, Kang JH, Bovee C, Wang J, Greenstein SH, Turalba A, Shen LQ, Brauner S, Boumenna T, Blum S, Levkovitch-Verbin H, Ritch R, Wiggs JL, Knepper PA, Pasquale LR. Nailfold capillary morphology in exfoliation syndrome. Eye. 31:698-707, 2017.
  87. Cousins CC, Alosco ML, Cousins HC, Chua A,. Steinberg EG,, Chapman,KR,Bing-CanarH, Tripodis Y,. Knepper PA Stern RA, Pasquale LR. Nailfold capillary morphology in Alzheimer’s disease dementia. J Alzheimer’s 66:601-611, 2018.
  88. Cousins CC, Chou JC, Greenstein SH, Brauner SC, Shen LQ, Turalba AV, Houlihan P, Ritch R, Wiggs JL, Knepper PA, Pasquale LR. Resting nailfold capillary blood flow in primary open-angle glaucoma. British Journal of Ophthalmology. 11:1136, 2018.
  89. Pfahler NM, Bielskus I, Giovingo MC, Knepper PA On the role of innate immune Toll-like receptor 4 in primary open-angle glaucoma In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2020 to 2022 pp57-72,  Kugler, Amsterdam
  90. Knepper PA, Pfahler NM, Bielskus I, Giovingo MC, Volpe NJ. On the prevention and treatment of progressive visual loss in primary open-angle glaucoma. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2020 to 2022 pp 1-16, Kugler, Amsterdam
  91. Bielskus I, Knepper PA, Pfahler NM. Diagnostic Techniques in Glaucoma – Healio https://cme.healio.com/glaucomacme.  Release Date: 2/18/2019.
  92. Knepper PA. Composition and method for inhibiting platelet aggregation.   US patent application 20190046466.  Feb. 2019.
  93. Knepper PA. Composition and method for inhibiting platelet aggregation.   US patent application 20190175522.  June 2019.
  94. Knepper PA. Composition and method for inhibiting platelet aggregation.  US patent application 15752458, 2019
  95. Knepper PA. Composition and method for inhibiting platelet aggregation. European Patent Office, EP 3337469A4, 2019.
  96. Pfahler NM, Bielskus I, Barry JL, Kakouri A, Giovingo MC,Volpe N,  Knepper PA. Microvascular biomarker:  Hemorrhages in nailfold capillaries in primary open angle glaucoma.  J Ophthalmology In Press 2020.
  97. Patel S, Kakouri A, Chaudhary S, Knepper PA, Pfahler NM, Samples J, Giovingo M. The effect of various media and probe angles on the power output of the Cyclo G6 Glaucoma Laser System. Lasers in Medical Science. In Press 2020.

Abstracts and Presentations

  1. Zeller EA, Knepper PA, Shoch D.  On the tonographic effects of monoamine oxidase inhibitors alone and in combination with adrenergic agents.  Invest Ophthalmol Vis Sci. (Suppl) 13:79, 1974.
  2. Knepper PA, Shoch D, Zeller EA. Differential effects of inhibitors on monoamine oxidase (MAO) A and B on the adrenergic system of the rabbit iris.  Invest Ophthalmol Vis Sci. (Suppl) 12:43, 1974.
  3. Breen M, Vitello LB, Weinstein HG, Knepper PA. Keratan sulfate-like substance as a function of age and corticosteroids in the brain and eye.  Fourth International Symposium on Glycoconjugates. 4:4, 1977.
  4. Weinstein HG, Breen M, Knepper PA. The glycosaminoglycans, age, and intraocular pressure. Proc Soc Complex Carbohydrates. No. 47, 1978.
  5. Weinstein HG, Knepper PA, Breen M. Age dependence of the rabbit eye to dexamethasone: Intraocular pressure and glycosaminoglycan distribution.  Gerontologist. 18:137, 1978.
  6. Weinstein HG, Breen M, Blacik LJ, Knepper PA. Comparative aging aspects of Fischer-344 and King rats: Brain glycosaminoglycans.  Gerontologist. 19:158, 1979.
  7. Perry AJ, Weinstein HG, Breen M, Knepper PA. Distribution of glycoconjugates and glycosaminoglycans in the human lens.  Proc Soc Complex Carbohydrates. No. 48, 1979.
  8. Breen M, Weinstein HG, Blacik LJ, Knepper PA. Comparative aspects of the glycosaminoglycan content in the cerebral cortex during development of the Fischer-344 and the King rat.  Proc Soc Complex Carbohydrates. No. 48, 1979.
  9. Breen M, Weinstein HG, Knepper PA.  Endo-B-D-galactosidase degradation of keratan sulfate from the brain.  Fed Proc. 39:1635, 1980.
  10. Knepper PA, Breen M, Weinstein H, Zaparackas Z. Bovine iris-ciliary body glycosaminoglycans.  Proc Intern Soc Eye Research. 1:68, 1980.
  11. Knepper PA, Farbman AI, Telser AG. Aqueous outflow pathway glycosaminoglycans. Invest Ophthalmol Vis Sci. (Suppl) 19:187, 1980.
  12. Knepper PA, Farbman AI, Telser AG. Glycosaminoglycans and the anterior chamber angle structures.  J Cell Biol. 87:128, 1980.
  13. Perry A, Weinstein HG, Breen M, Knepper PA. Distribution of complex carbohydrates in the bovine lens.  Proc Soc Complex Carbohydrates. No. 67, 1980.
  14. Weinstein HG, Perry AJ, Knepper PA, Breen M. Glycoproteins in decapsulated bovine lens.  Fed Proc 40:844, 1981.
  15. Knepper PA, Zaparackas ZG. Glycosaminoglycans and aqueous outflow resistance. Invest Ophthalmol Vis Sci (Suppl). 20:23, 1981.
  16. Breen M, Weinstein HG, Knepper PA. Proteoglycans in the cerebral cortex.  Fed Proc. 40:1841, 1981.
  17. Knepper PA. Glycosaminoglycans and aqueous outflow resistance.  Dissertation Abstracts International. Vol 41, No. 9, 1981.
  18. Knepper PA, Zaparackas ZG, McLone DG, Breen M, Weinstein HG, Blacik L. Glycoconjugates of the anterior segment of the eye.  Proc Soc Complex Carbohydrates. No. 50, 1981.
  19. Knepper PA, Breen M, Weinstein HG, McLone DG. Topography of brain glycosaminoglycans.  Gerontologis.t 21:151, 1981.
  20. Zaparackas ZG, Knepper PA. Chelating agents and aqueous outflow resistance.  Invest Ophthalmol Vis Sci (Suppl). 22:93, 1982.
  21. Knepper PA, McLone DG. Glycosaminoglycans and the human aqueous outflow pathway.  5th International Congress of Eye Research. Sec. C-3/5:100, 1982.
  22. Collins J, Zaparackas ZG, Knepper PA. Anterior segment complex carbohydrate synthesis in vitro.  Invest Ophthalmol Vis Sci (Suppl). 22:31, 1982.
  23. Knepper PA, Collins J, Zaparackas ZG, Weinstein H, Breen M. Human trabecular meshwork glycosaminoglycans.  Invest Ophthalmol Vis Sci (Suppl). 22:93, 1982.
  24. Breen M, Weinstein HG, Knepper PA. Rat brain synaptosomal membranes: Morphology and chemistry after ethanol.  Eighth International Subcellular Methodology Forum:                                   Membrane located receptors.  University of Surrey, Guildford, England, 12-15 July 1982.
  25. Weinstein HG, Breen M, Knepper PA.  Sialoglycoproteins in synaptic membranes after alcohol ingestion.  Proc Soc Complex Carbohydrates. No. 19, 1982.
  26. Weinstein HG, Breen M, Knepper PA. Sialoglycoproteins in synaptic membranes of developing brain.  Gerontology. 22:233, 1983.
  27. Suwa J, Collins J, McLone DG, Breen M, Knepper PA. Tunicamycin and neurulation in embryo culture.  Fed Proc. 42:756, 1983.
  28. Collins JA, Knepper PA. Dexamethasone induced ocular hypertension and in vitro complex carbohydrate synthesis.  Invest Ophthalmol Vis Sci (Suppl). 24:86, 1983.
  29. Knepper PA, Sakol PJ, Beauchamp GR. Anterior segment anomalies in the OEL/OEL mouse.  Invest Ophthalmol Vis Sci (Suppl). 24:62, 1983.
  30. Breen M, Weinstein HG, Knepper PA.  Age-related molecular interactions of brain membrane surface sialoglycoproteins.  Fed Proc. 42:2123, 1983.
  31. Weinstein HG, Breen M, Knepper PA. Effect of ethanol and age on brain membrane glycoconjugates.  Fed Proc. 42:2124, 1983.
  32. Breen M, Weinstein HG, Knepper PA, Snyder AK, Singh SP. Surface glycoconjugates in brain membranes:  Effect of age and alcohol.  Seventh International Symposium on Glycoconjugates, Lund-Ronneby, Sweden, July 17-23, 1983.
  33. Naidich TP, McLone DG, Knepper PA. Biochemical and morphological studies on primary and secondary neural tube defects: Specific evidence for the mechanisms of spina bifida.  Eleventh Congress of the European Society for Neuroradiology. 1983.
  34. Breen M, Weinstein HG, Blacik LJ, Knepper PA. Interaction of synaptic membrane surface glycoconjugates with lectins:  Changes during growth.  Fed Proc. 43:317, 1984.
  35. Poznanski S, McLone DG, Lubeck D, Beauchamp G, Knepper PA. Primary congenital aphakia in the SP/SP mouse.  Invest Ophthalmol Vis Sci (Suppl). 25:67, 1984.
  36. Collins JA, Knepper PA. Effect of selected steroids on intraocular pressure and glycosaminoglycan synthesis.  Invest Ophthalmol Vis Sci (Suppl). 25:96, 1984.
  37. Lubeck D, Beauchamp GR, Knepper PA. FITC and rhodamine labeled lectins and the development of the trabecular meshwork.  Invest Ophthalmol Vis Sci (Suppl). 25:99, 1984.
  38. Weinstein HG, Breen M, Blacik LJ, Knepper PA. Synaptic membrane glycoconjugates: Lectins and ethanol ingestion.  Fed Proc. 43:1708, 1984.
  39. Collins JA, Breen M, Knepper PA.  Effect of steroids on glycosaminoglycan synthesis in the rabbit eye.  Proc Soc Complex Carbohydrates. No. 19, 1984.
  40. Hopp LM, Breen M, Weinstein HG, Blacik LJ, Knepper PA.  A synaptosomal preparation for studying human brain glycoconjugates.  Proc Soc Complex Carbohydrates. No. 92, 1984.
  41. Knepper PA, Goossens W, Beauchamp G, Morin JD. Glycoconjugates and congenital glaucoma.  Invest Ophthalmol Vis Sci (Suppl). 26:111, 1985.
  42. Collins JA, Knepper PA. Analysis of human trabecular meshwork glycosaminoglycans by high performance liquid chromatography.  Invest Ophthalmol Vis Sci (Suppl). 26:333, 1985.
  43. Goossens W, Fowell S, Collins JA, Knepper PA. Localization of trabecular meshwork glycosaminoglycans in steroid treated rabbit eyes by computer-aided microspectrophotometry.  Invest Ophthalmol Vis Sci (Suppl). 26:111, 1985.
  44. Gum GG, Gelatt KN, Collins JA, Knepper PA. Analysis of glycosaminoglycans in trabecular meshwork of glaucoma and normal canine eyes.  Invest Ophthalmol Vis Sci (Suppl). 27:164, 1986.
  45. Goossens W, Higbee RG, Palmberg PF, Knepper PA. Histochemical identification of glycosaminoglycans in primary open-angle glaucoma.  Invest Ophthalmol Vis Sci (Suppl). 27:162, 1986.
  46. Lubeck DM, Vanden Hoek TL, Knepper PA. FITC labeled lectins and analysis of retinal degeneration in the nervous (NR/NR) mouse.  Invest Ophthalmol Vis Sci (Suppl). 27:311,1986.
  47. Vanden Hoek TL, Goossens W, Knepper PA. Glycoconjugates in the primate (M. fascicularis) trabecular meshwork.  Invest Ophthalmol Vis Sci (Suppl). 27:162, 1986.
  48. Collins JA, Gum GG, Palmberg PF, Knepper PA. Microscale analysis of glycosaminoglycans from single human trabecular meshwork.  Invest Ophthalmol Vis Sci (Suppl). 27:162, 1986.
  49. Herman H, McLone DG, Higbee RG, Goossens W, Knepper PA. Glycoconju-gates and the development of the cerebrospinal fluid outflow pathway in the mouse.  Society For Neuroscience. 12(2):866, 1986.
  50. Johnson TM, Higbee RG, Goossens W, McLone DG, Knepper PA. Neurulation: A biochemical analysis of micro-dissected neuroepithelium in normal and abnormal neurulation.  Society For Neuroscience. 12(2):1360, 1986.
  51. Breen M, Weinstein HG, Knepper PA, Blacik LJ, Moss LR: Concanavalin A and wheat germ agglutinin binding proteins in mouse cerebellum dur.ng postnatal development. Proc Soc Complex Carbohydrates. No. 45, 1986.
  52. Knepper PA, Goossens W, Higbee RG, Palmberg PF. Lectins, glycoconjugates and pseudoexfoliation glaucoma.  Invest Ophthalmol Vis Sci (Suppl).  28(3):132, 1987.
  53. Collins JA, Higbee RG, Goossens W, Palmberg PF, Knepper PA. Biochemical isolation of iris GAG’ase-resistant material in primary open-angle glaucoma.  Invest Ophthalmol Vis Sci (Suppl). 28(3):130, 1987.
  54. Higbee RG, Beauchamp GR, Goossens W, Knepper PA.  Inherited corneal endothelial dystrophy in the OEL/+ mouse: A model for Fuch’s endothelial dystrophy.  Invest Ophthalmol Vis Sci (Suppl). 28(3):171, 1987.
  55. Gum GG, Goossens W, Knepper PA. Histochemical localization of glycosaminoglycans in the glaucomatous and normal canine eye.  Invest Ophthalmol Vis Sci (Suppl). 28(3):131, 1987.
  56. Breen M, Weinstein HG, Knepper PA. Glycosylated proteins in the developing mouse cerebellum synaptic membrane.  Fed Proc. 46:963, 1987.
  57. Breen M, Moss LR, Knepper PA, Blacik LJ, Weinstein HG. Concanavalin A binding protein in the normal and reeler mutant mouse.  Proceedings of the IXth International Symposium on Glycoconjugates. No. 46, 1987.
  58. Sinson GP, Breen M, Higbee RG, Goossens W, McLone DG, Knepper PA. Carbohydrates and histogenesis in cerebellar development in the abnormal (Reeler) and normal mouse.  Society For Neuroscience. 13(2):1120, 1987.
  59. Nelson LI, Ersahin Y, Higbee RG, McLone DG, Knepper PA. WGA- and Con A-binding glycoproteins and the process of neurulation.  Society For Neuroscience. 13(1):254, 1987.
  60. Ersahin Y, Nelson LI, Higbee RG, McLone DG, Knepper PA. Vitamin A-induced suppression/enhancement of protein glycosylation and neurulation.  Society For Neuroscience. 13(2):926, 1987.
  61. Knepper PA, Hvizd MG, Higbee RG, Swoboda P, Palmberg E, Ramachandran B, Palmberg PF.  Heparitin sulfates and GAG-ase resistant material of normal human and primate trabecular meshwork.  Invest Ophthalmol Vis Sci (Suppl). 29:128, 1988.
  62. Sires BS, Vanden Hoek TL, Hvizd MG, DeSantis L, Knepper PA. Trabecular meshwork cellular responses to growth factors in primary organ culture.  Invest Ophthalmol Vis Sci (Suppl). 29:126, 1988.
  63. Higbee RG, Davis AB, Brown G, Knepper PA. Corneal endothelial cell response to basic fibroblast growth factor in primary organ culture.  Invest Ophthalmol Vis Sci (Suppl). 29:256, 1988.
  64. Vanden Hoek TL, Higbee RG, Goossens W, Beauchamp G, Knepper PA. Carbohydrate-specific probes and congenital glaucoma in the rabbit.  Invest Ophthalmol Vis Sci (Suppl). 29:238, 1988.
  65. Goossens W, Higbee RG, Vanden Hoek TL, Brown G, Knepper PA. Ultra-structual and immunocytochemical localization of chondroitin sulfates in human trabecular meshwork. Invest Ophthalmol Vis Sci (Suppl). 29:129, 1988.
  66. Breen M, Moss LR, Weinstein HG, Knepper PA. Synaptic membrane glycoconjugates in the reeler mouse.  FASEB J. 2:A319, 1988.
  67. Higbee RG, Fiacco JL, Vanden Hoek TL, Goossens W, McLone DG, Knepper PA. Oligosaccharides and abnormal neurulation in the delayed splotch mutant.  Society Neuroscience. 14:829, 1988.
  68. Weinstein HG, Breen M, Knepper PA. Sialoglycoproteins in cerebellar synaptic membranes during development: The Reeler mouse.  American Association For Advancement of Sciences. No. 409, p 192, 1989.
  69. Vanden Hoek TL, Ritch R, Goossens W, Knepper PA. Identification of carbohydrates by FITC-lectin staining in trabeculectomy specimens from pigmentary, pseudoexfoliation and POAG.  Invest Ophthalmol Vis Sci (Suppl). 30(3):224, 1989.
  70. Higbee RG, Haggard K, Moll H, Clark A, Goossens W, Hvizd MG, Knepper PA. Biochemical markers in aqueous humor of increased intraocular pressure.  Invest Ophthalmol Vis Sci (Suppl). 30(3):29, 1989.
  71. Goossens W, Hvizd MG, Higbee RG, Palmberg PF, Knepper PA. GAG stratification in normal and primary open-angle glaucoma JCT.  Invest Ophthalmol Vis Sci (Suppl). 30(3):205, 1989.
  72. Knepper PA, Hvizd MG, Goossens W, Higbee RG, Gum GG, Palmberg PF. GAG profile of the human TM in primary open-angle glaucoma.  Invest Ophthalmol Vis Sci (Suppl). 30(3):224, 1989.
  73. Tschumper RC, Johnson DH, Acott TS, Knepper PA. Glycosaminoglycans of human TM in organ culture.  Invest Ophthalmol Vis Sci (Suppl). 30(3):224, 1989.
  74. Nakahara S, Fiacco J, McLone DG, Hvizd MG, Higbee RG, Knepper PA. Neural tube defects induced by amniotic injection of Con A in mouse embryos.  Society for Neuroscience. 15:685, 1989.
  75. Robinson S, McLone DG, Dauser RC, Higbee RG, Goossens WG, Knepper PA. FITC-Con A binding in neural tube defects induced by hypothermia during neurulation in chick embryos.  Society for Neuroscience. 15:686, 1989.
  76. Weinstein HG, Breen M, Knepper PA. Murine developmental biology: Cerebral synaptosomal junction complex carbohydrates.  FASEB J. 3(3):A328, 1989.
  77. Abramson JL, Hvizd MG, Goossens W, Higbee RG, Knepper PA. Topologic study of glycoconjugates in the primate optic nerve.  Invest Ophthalmol Vis Sci (Suppl). 31:99, 1990.
  78. DeSantis L, Garthwaite C, Knepper PA. Dexamethasone-induction of ocular hypertension in the primate.  Invest Ophthalmol Vis Sci (Suppl). 31:99, 1990.
  79. Higbee RG, Knepper PA. A method for storage and analysis of proteins and glycoproteins of the trabecular meshwork.  Invest Ophthalmol Vis Sci (Suppl). 31:99, 1990.
  80. Steely HT, Wilson K, Clark A, Knepper PA. Biochemical similarities of human trabecular meshwork and lamina cribrosa.  Invest Ophthalmol Vis Sci (Suppl). 31:455, 1990.
  81. Knepper PA, Hvizd MG, McLone DG, Higbee RG, Goossens W, Palmberg PF. GAG profile of normal and POAG lamina cribrosa.  Invest Ophthalmol Vis Sci (Suppl). 31:564, 1990.
  82. Niforatos W, Hvizd MG, Knepper KL, Higbee RG, Nakahara S, McLone DG, Knepper PA.  Carbohydrate binding proteins in embryonic spinal cord and brain.  Society for Neuroscience. 16:642, 1990.
  83. Nakahara S, Goossens W, Higbee RG, Inagaki T, McLone DG, Knepper PA. Vitamin A-induced neural tube defect with Chiari II malformation in mice.  Society for Neuroscience. 16:790, 1990.
  84. Inagaki T, Goossens W, Nakahara S, McLone DG, Knepper PA. The arachnoid and subarachnoid space in the hy-3/hy-3 mouse with hydrocephalus.  Society for Neuroscience. 16:1152, 1990.
  85. Knepper PA, Garthwaite C, Hvizd MG, Goossens W, DeSantis, L. Effect of 17-alpha-methyl-testosterone on IOP and GAG profile of dexamethasone-induced ocular hypertension in primates.  Invest Ophthalmol Vis Sci (Suppl). 32:871, 1991.
  86. Niforatos, W, Goossens W, Ritch R, Knepper, PA. Microanalysis of glycosaminoglycans of the trabecular meshwork.  Invest Ophthalmol Vis Sci (Suppl). 32:875, 1991.
  87. Inagaki T, Goossens W, Higbee RG, McLone DG, Knepper PA. Vitamin A induced alteration in secondary neurulation.  Society for Neuroscience. 17:1251, 1991.
  88. Wang K, Goossens W, Higbee RG, McLone DG, Knepper PA: Differentiation process of IV ventricle outlets in mice.  Society for Neuroscience. 17:1.52, 1991.
  89. Mayanil CSK, Niforatos W, Higbee R, McLone DG, Knepper PA. Lactosamine-containing glycoproteins in embryonic normal and abnormal (NTD) spinal cord.  Society for Neuroscience. 17:1252, 1991.
  90. Nakahara S, McLone DG, Knepper PA. A unified theory of the cause of the Chiari II malformation.  Annual Meeting of the Japanese Neurosurgical Society. 1991.
  91. Johnson DH, Knepper PA. The effects of ascorbate and dexamethasone on GAGs, IOP, and ultrastructure of human TM in organ culture.  Invest Ophthalmol Vis Sci (Suppl). 33:1164, 1992.
  92. Knepper PA, Aronyk KE, Curan EL. Trabecular meshwork capacitation.  Invest Ophthalmol Vis Sci (Suppl). 33:1164, 1992.
  93. Higbee RG, Mayanil CSK, Knepper PA. Microscale analysis of the molecular weight of glycosaminoglycans.  Invest Ophthalmol Vis Sci (Suppl). 33:1163, 1992.
  94. Knepper PA, Fadel JR, Mayanil CSK, Millichap J. Influence of molecular weight and concentration of hyaluronic acid on flow rates in vitro.  Invest Ophthalmol Vis Sci (Suppl). 34:1139, 1993.
  95. Covici S, Fadel JR, Mayanil CSK, Ritch R, Knepper PA. Surface tension properties of hyaluronic acid.  Invest Ophthalmol Vis Sci (Suppl). 34:1202, 1993.
  96. Clark AF, McNatt L, Knepper PA. Angiostatic steroids as a new class of IOP lowering compounds.  Invest Ophthalmol Vis Sci (Suppl). 35: 1483, 1994.
  97. Mayanil CSK, George T, McLone M, Knepper PA. Small eye and Pax-6 antisense oligonucleotide probe.   XI International Congress of Eye Research (Suppl 1). 59:S.93, 1994.
  98. Knepper PA, Mayanil CSK, Goossens W. Hyaluronate receptor, CD44 and hyaluronate synthase in human eyes.  XI International Congress of Eye Research  (Suppl 1). 59:S.75, 1994.
  99. Mayanil CSK, Goossens W, Knepper PA.  Age-related changes in the expression of hyaluronan receptor–CD44–and hyaluronate synthase in human trabecular meshwork. Invest Ophthalmol Vis Sci (Suppl). 36:S129, 1995.
  100. Knepper PA, Mayanil CSK, Byrne RW, Goossens W.  Pax 3 transcription factor binds to hyaluronan.  Invest Ophthalmol Vis Sci (Suppl). 36:S127, 1995.
  101. Mayanil CSK, Castellon R, Knepper PA. Role of gp47 in neurite outgrowth in PC12 cells.  Neuroscience. 21:795, 1995.
  102. Lindemulder SJ, Goossens W, Mayanil CSK, Knepper PA. CD44 isoforms in human trabecular meshwork. Invest Ophthal Vis Sci. 37:S822, 1996.
  103. Knepper PA, Mayanil CSK, Hayes E, Lindemulder SJ. Transcription factors are present in fetal calf serum.  Invest Ophthal Vis Sci. 37:S824, 1996.
  104. Knepper PA, Mayanil CSK, Lindemulder S. Hyaluronan binding motif.  XII International Congress of Eye Research (Suppl). 63: 5157, 1996.
  105. Mayanil CSK, Knepper PA. Exon shuffling and glycosylation of CD44 isoforms in human trabecular meshwork.  XII International Congress of Eye Research (Suppl). 63:5158, 1996.
  106. Knepper, PA, Mayanil CSK, Guzelbag E, McLone DG. Transcription factors are present in avian yolk and albumin.  Developmental Biology. 175:382, 1996.
  107. Lukas R, Wills J, Davis E, Zaparackas ZG, Mayanil CSK, Knepper PA. Transcription factors are present in rabbit aqueous fluid.   Invest Ophthalmol Vis Sci. 38:S1128, 1997.
  108. Knepper PA, Lukas R, Wills J, Goossens W, Mayanil CSK. Hyaluronic acid receptors of the human trabecular meshwork.  Invest Ophthalmol Vis Sci. 38:S451, 1997.
  109. Wills J, Mayanil CSK, Goossens W, Knepper PA. Receptor for HA mediated motility (RHAMM) in the trabecular meshwork and ciliary body of normal and primary open angle glaucoma.  Invest Ophthalmol Vis Sci. 38:564, 1997.
  110. Nye JS, Balkin NE, Lucas H, Knepper PA, McLone DG, Charrow J. Severe variant of Waardenburg syndrome with meningomyelocele in patients with intersitial deletion of 2q35 and the PAX3 gene.  The Society for Pediatric Research. 1997.
  111. Holgren C, Ramsey DJ, Goossens W, Mayanil CSK, Wertz RD, Knepper PA. Aqueous humor and an improved gradient method for analysis of hyaluronic acid molecular weight distribution.  Invest Ophthalmol Vis Sci. 39:S705, 1998.
  112. Mayanil CSK, Holgren C, Goossens W, Ritch R Wertz RD, Knepper, PA. CD44 in normal human aqueous humor.  Invest Ophthalmol Vis Sci. 39:S931, 1998.
  113. Knepper PA, Lukas R, Goossens W, Mayanil CSK, Zaparackas, ZG. Soluble CD44 is decreased in primary open-angle glaucoma.  Invest Ophthalmol Vis Sci. 39:S705, 1998.
  114. Knepper, PA, Holgren C, Wertz RD, Goossens W, Krupin T, Allingham RR. Primary open-angle glaucoma aqueous has increased CD44. Invest Ophthalmol Vis Sci. 40:S503,1999.
  115. Knepper PA, Goossens W, Zaparackas Z, Wertz,RD, Wang DO. Localization of soluble CD44 in primary open-angle glaucoma aqueous outflow pathway. Invest Ophthalmol Vis Sci. 41:S504, 2000.
  116. Wang DO, Goossens W, Knepper PA. Extracellular matrix remodeling: the possible role of MMP-9 and CD44. Invest Ophthalmol Vis Sci. 41:S511, 2000.
  117. Clark AF, DeFaller J, Knepper PA, Robin A, Goode SM. IOP lowering activity of anecortave acetate in rabbit and human glucocorticoid-induced ocular hypertension. Invest Ophthalmol Vis Sci. 41:S767, 2000.
  118. Knepper PA. CD44 in outflow pathways.  XIV International Congress of Eye Research. 71:S155,2000.
  119. Choi J, Miller, AM, Knepper PA. Hyaluronic acid-binding proteins. Invest Ophthalmol Vis Sci. 42:S139, 2001.
  120. Miller AM, Choi J, Knepper PA. Inter-alpha-trypsin inhibitor in aqueous humor. Invest Ophthalmol Vis Sci. 42:S139, 2001.
  121. Knepper PA, Miller AM, Choi J, Land D, Clark A. Trabecular meshwork cell apoptosis due to ligation of CD44 by anti-CD44 antibody.  Invest Ophthalmol Vis Sci, 42:S144, 2001.
  1. Knepper PA, Choi J, Miller AM, Wertz R, Ritch R, Zhang W, Yue BYJT. sCD44 causes cell death of bovine trabecular meshwork cells.  Invest Ophthalmol Vis Sci. ARVO meeting 2002.
  2. Choi J, Yue BYJT, Miller AM, Knepper PA. Influence of sCD44 on the expression of erbB2, a cell survival pathway, and rescue of bovine trabecular meshwork cells.  Invest Ophthalmol Vis Sci. ARVO meeting, 2002.
  3. Whitmer S, Miller AM, Goossens W, Choi J, Knepper PA. POAG trabecular meshwork glycosaminoglycans: influence of hyaluronic acid and chondroitin sulfate on initial flow rates.  Invest Ophthalmol Vis Sci. ARVO meeting 2002.
  4. Goossens W, Wertz R, Miller AM, Choi J,. Allingham RR, Knepper PA. MMP-9 in aqueous of normal and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. ARVO meeting 2002.
  5. Miller AM, Choi J, Knepper PA. Does the vitreous humor act as a reservoir for cytotoxic sCD44?  Invest Ophthalmol Vis Sci. ARVO meeting 2002.
  6. Samples JR, Choi J, Miller AM, Knepper PA. Cytokine induced production of sCD44 in the human eye.  Invest Ophthalmol Vis Sci. ARVO meeting 2002.
  7. Knepper PA, Miller AM, Choi J, Doherty ER, Wertz R,Ritch R, Allingham RR, Wax MB, Palmberg PF, Samples JR.  Is POAG an adaptive senescence phenomenon? Invest Ophthalmol Vis Sci. ARVO meeting 2003.
  8. Miller AM, Choi J, Yue BYJT, Shen X, Samples JR, Doherty ER,  Knepper PA. Metabolic stress causes NF-κB activation and CD44 shedding in cultured TM cells. Invest Ophthalmol Vis Sci. ARVO meeting 2003.
  9. Doherty ER, Choi J, Yue BYJT, Miller AM, Shen X,  Knepper PA. Trabecular meshwork MT1-MMP is up-regulated in response to metabolic stress.  Invest Ophthalmol Vis Sci. ARVO meeting 2003.
  10. Goossens W, Miller AM, Choi J, Doherty ER, Whitmer S, Knepper PA. Percolation test of trabecular meshwork glycosaminoglycans. Invest Ophthalmol Vis Sci. ARVO meeting
  11. Choi J, Yue BYJT,  Doherty ER, Miller AM, Agarwal N, Thotz SY, Clark AF, Knepper PA.  sCD44 is neurotoxic to retinal ganglion cells.  Invest Ophthalmol Vis Sci. ARVO meeting
  12. Knepper PA, Choi J, Miller AM, Nolan NJ, Witkowski K, Allingham RR, Ritch R, Samples JR. A possible mechanism for increased IOP as a risk factor in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. ARVO meeting
  13. Nolan NJ, Choi J, Wertz RD, Knepper PA. sCD44 phosphorylation in normal and primary open-angle glaucoma aqueous humor. Invest Ophthalmol Vis Sci. ARVO meeting
  14. Choi J, Nolan NJ, Yue BYJT, Samples JR, Knepper PA. sCD44 aggregation, neurotoxicity and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. ARVO meeting
  15. Knepper PA. Role of CD44 in cross-talk between ciliary epithelium and outflow pathway. Invest Ophthalmol Vis Sci. ARVO meeting 2004.
  16. Nolan MJ, Patel N, Jablon GE, Yue BYJT, Knepper PA. Aqueous humor sCD44 and visual field loss in POAG.  Invest Ophthalmol Vis Sci. ARVO meeting, abstract 3777,
  17. Nolan MJ, Yue BYJT, Samples JR, Knepper PA. Oxidative stress induces secretion of hypophosphorylated soluble CD44 by trabecular meshwork cells in culture. Invest Ophthalmol Vis Sci. ARVO annual meeting, 2006.
  18. Knepper PA, Nolan MJ, Wirtz MK, Samples JR, Allingham RR, Wiggs JL, Yue BYJT. Regulation of ABC transporters and glaucoma: New Ideas.  Invest Ophthalmol Vis Sci. ARVO annual meeting, 2006.
  19. Knepper PA, Nolan MJ. Regulation of multidrug resistance ABC transporter by hyaluronic acid and soluble CD44. ISER meeting, 2006.
  20. Knepper PA, Koga T, Nolan M, Yue BYJT, Sheppard A, Clark A. Multidrug resistance proteins and trabecular meshwork. Invest Ophthalmol Vis Sci.  ARVO annual meeting, 2007.
  21. Nolan M, Koga T, Samples JR, Yue BYJT, Knepper PA. Internalization of sCD44 in trabecular meshwork cells in culture. Invest Ophthalmol Vis Sci. ARVO annual meeting, 2007
  22. Giovingo MC, Nolan MJ, Koga T, Yue BYJT, Wertz RD, Ritch R, Shepard A, Clark AF, Wax MB, Knepper PA. Aqueous Humor sCD44 concentration in diabetes and primary Open-Angle Glaucoma. Invest Ophthalmol Vis Sci. ARVO annual meeting, 2008.
  23. Nolan MJ, Koga T, Yue BYJT, Giovingo MC, Shepard A, Clark AF, Wax MB, Samples JR, Knepper PA.  Caveolin-1 expression in trabecular meshwork cells. Invest Ophthalmol Vis Sci ARVO annual meeting, 2008.
  24. Shepard AR, Nolan MJ, Millar JC, Pang LH, Luan T, Jacobson N, Wax MB, Clark AF, Knepper PA. CD44 overexpression causes ocular hypertension in the mouse.  Invest Ophthalmol Vis Sci. ARVO annual meeting, 2008.
  25. Knepper PA, Beverley RM, McCarty RD, Nolan MJ, Yue BYJT, Samples JR. Wnt signaling and trabecular meshwork lipid rafts.  Invest Ophthalmol Vis Sci. ARVO annual meeting 2009.
  26. Beverley RM, Nolan MJ, McCarty RD, Yue BYJT, Samples JR, Knepper PA. Omega-3 protects trabecular meshwork from metabolic stress. Invest Ophthalmol Vis Sci. ARVO annual meeting 2009.
  27. McCarty RD, Nolan MJ, Beverley RM, Quinn K, Yue BYJT, Samples JR., Knepper PA. Gamma Secretase and trabecular meshwork stress. Invest Ophthalmol Vis Sci ARVO annual meeting 2009.
  28. McCarty RD, Beverley RM, Giovingo MC, Nolan MJ, Yue BYJT, StamerWD, Knepper PA. Differential pattern of junctional complex lipid raft proteinsi in human conventional outflow. Invest Ophthalmol Vis Sci. ARVO annual meeting 2010.
  29. Giovingo MC, McCarty RD, Beverley RM, Nolan MJ, Samples JR, Yue BYJT, Knepper PA. Soluble CD44 increaseso outflow resistance in porcine organ cultures.  Invest Ophthalmol Vis Sci ARVO annual meeting 2010.
  30. Beverley RM, McCarty RD, Giovingo MC, Nolan MJ, Samples JR, Yue BYJT, Knepper PA.  De-aggregation of soluble CD44 prevents cytotoxicity. Invest Ophthalmol Vis Sci ARVO annual meeting 2010.
  31. Schwartz, SN., Beverley RM, Giovingo MC, McCarty RD, Mayer, JP, Knepper, PA. Actin reorganization (CLANs) Induced by sCD44-treatment in trabecular meshwork cells.  Invest Ophthalmol Vis Sci. ARVO annual meeting,  May 2011.
  32. McCarty RD, Mayer JP, Schwartz SN, Knepper PA. Endogeneous hyaluronidase and hyaluronidase inhibitors in POAG aqueous.  Invest Ophthalmol Vis Sci. ARVO annual meeting Abstract No 11-A-3191, May 2011.
  33. Knepper PA, McCarty RD, Mayer JP, Schwartz SN, Nolan MJ, Samples JR, Liebmann JM, Ritch R. Low molecular weight hyaluronic acid in POAG aqueous. Invest Ophthalmol Vis Sci. ARVO annual meeting Abstract No.11-A-3192, May 2011.
  34. Mayer JP, Kasniunas A, McCarty RD, Schwartz SN, Yue, BYJT, Knepper PA. Toll-like Receptor 4, low molecular weight hyaluronic acid and cytokine response in trabecular meshwork cells. Invest Ophthalmol Vis Sci. ARVO annual meeting Abstract No. 11-A-3333, May 2011.
  35. Giovingo M, McCarty RD, Beverley R, Nolan M, Grybauskas A, Burdi RA, Wagner E, Knepper PA. DHA increases outflow resistance in porcine organ cultures. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:2494, May 2012.
  36. Knepper PA, McCarty RD, Grybauskas A, Mayer JP, Burdi RA, Wagner E, Samples JR, Liebmann JM, Ritch R. Low molecular weight hyaluronic acid and hyaluronic acid binding protein-2: a theory for hemorrhages in POAG. Invest Ophthalmol Vis Sci.  Meeting E-Abstract:2797, May 2012.
  37. Wagner EL, Grybauskas A, Burdi RA, Walker L, Yue B, Samples JR, Knepper PA. Naloxone as a neuroprotectant in glaucoma: its role in the TLR4 pathway and innate immunity. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:3474, May 2012.
  38. Grybauskas A, Wagner EL, Burdi RA, Walker L, Knepper PA. TLR-4 innate immune differential response to three dietary fatty acids challenged with low molecular weight hyaluronic acid, a TLR-4 ligand. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:6615. May 2012
  39. Burdi RA, Wagner EL, Walker L, Grybauskas A, McCarty RD, Mayer JP, Knepper PA. Hemopexin: an inhibitor of hyaluronidase-2. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:6616, May 2012.
  40. Grybauskas A, Walker L, Wanger E, Rurdi R, McCarty R, Samples J, Knepper PA. New idea of neuroprotection: chondroitin disaccharides and toll-like-receptor 4. XX. International Society for Eye Research. Abstract P248; Berlin Germany2012.
  41. Knepper PA. Innate immunity and primary open-angle glaucoma. XX. International Society for Eye Research. Abstract 10; Berlin Germany 2012.
  42. Kuprys PV, Grybauskas A, Skuran KJ, Knepper PA.  POAG blood and hyaluronic acid challenged monocytes upregulate CD44s and isoforms: A new biomarker? Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:6238, May 2013.
  43. Skuran KJ, McCarty R, Grybauskas A, Kuprys P, Samples JR, Knepper PA. Nailfold hemorrhages and primary open-angle glaucoma: More than what meets the eye. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:1881, May 2013.
  44. Grybauskas A, Skuran KJ, Kuprys PV, Knepper PA. Inhibition of innate immune response alters detoxification capacity of ABCB1 transporters in trabecular meshwork cells. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:427, May 2013.
  45. Kuprys PV, Forte S, Wanderling C, Walker L, Grybauskas A, Samples JR, Zaparackas Z, Yue B, Knepper PA.  Primary open-angle glaucoma patients have superactivated platelets.  A sticky conundrum. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:531, May 2014.
  46. Knepper PA, Hill G, Hawkins S, Wanderling C, Kuprys PV, Forte S, Velapapudi C, Samples JR, Giovingo MC, Volpe N. Nailfold hemorrhages and dilated capillaries separate POAG from NTG.  Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:4751, May 2014.
  47. Forte S, Grybauskas A, Kuprys PV, Wanderling C, Walker L, Velagapudi C, Samples JR, Johnson A, Zaparackas ZG, Knepper PA. Platelet Toll-like receptor 4 expression in POAG: The innate immune system. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:4523, May 2014.
  48. Wanderling C, Kuprys PV, Forte S, Grybauskas A, Skuran K, Johnson A, Zaparackas Z, Knepper PA. On the role of intermediate monocyte subtypes in POAG. Possible cause of disease propagation. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:4518, May 2014.
  49. Green K, Norkett W, Grybauskas A, Velagapudi C, Samples JR, Pasquale LR, Knepper PA.Mathematical modeling of shear stress and shear rate: Implications for NTG and POAG. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:2765, May 2015.
  50. Grybauskas A, Kuprys PV, Norkett WM, Green K, Knepper PA. Improved method for characterizing three platelet activation states in glaucoma. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:2410, May 2015.
  51. Wanderling C, Ren A, Norkett WM, Green K, Giovingo M, Pasquale LR, Knepper PA. Examining systemic microvascular abnormalities in primary open-angle glaucoma using nailfold videomicroscopy. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:2741, May 2015.
  52. Norkett WM, Green K, Ren A, Walker L, Tanna AP, Pasquale LR, Knepper PA.Thrombi to hemorrhages: The ins and outs of microvascular disease in glaucoma. Invest Ophthalmol Vis Sci. ARVO Meeting E-Abstract:2740, May 2015.
  53. Pasquale LR, Ren A, Hanyda A, Kange JH, Green K, Knepper PA. Nailfold microvascular abnormalities in primary open-angle glaucoma. American Ophthalmological Society Abstract, Newport Beach RI, May 2015.
  54. Carey K, Bielskus I, Patel M, Green K, Lelis A,Wanderling C, Kuprys P, Knepper PA. A new look at platelet inhibition and neuroprotection. Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 2561, 2016.
  55. Giovingo M, Green K, Carey K, Bielskus I, Patel M, Pasquale L,  Patrianakos T, Samples JR, Martin, Elizabeth, Knepper PA. The multiple hit theory of primary open angle glaucoma Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 3015, 2016.
  56. Knepper PA, Cousins C, Carey K, Bielskus I,  Patel M, Volpe NJ, Patrianakos T, Giovingo M, Pasquale LF, Stern R.   Alzheimer’s disease and primary open angle glaucoma may share nailfold capillary abnormalities. Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 2977, 2016.
  57. Bielskus I, Patel M, Forte S, Norkett W, Kuprys P, Carey K, Knepper PA. Novel anti-platelet compounds to protect collagen activated platelets via GPVI: Implications for microvascular disease in POAG. Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 2549, 2016.
  58. Patel M, Carey K, Bielskus I, Green K, Lelis A, Knepper PA. Endothelial progenitor cell culture as a potential autologous transplant treatment for POAG Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 2560, 2016.
  59. Knepper PA, Giovingo M, Carey K, Bielskus I, Miazga M, Pfahler NM, Volpe NJ. Viscosity in POAG: effects of shear rate and cross-linking. Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 736, 2017.
  60. Miazga MD, Bielskus I, Pfahler NM, Tanna AP, Volpe NJ, Giovingo M, Zaparackas Z, Knepper PA. High myopia in POAG and nailfold hemorrhages. Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 746, 2017.
  61. Pfahler NM, Bielskus I, Miazga M, Kaufman E, Mandich M, Knepper PA. A Novel Method to Decrease SAP-Induced Prothrombotic Activity in POAG and Alzheimer’s Disease. Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 4599, 2017.
  62. Giovingo M, Carey K, Bielskus I, Miazga M, Pfahler NM, Knepper PA. The clot may thicken in primary open angle glaucoma. Invest Ophthalmol Vis Sci. ARVO Meeting E-abstract 4598, 2017.
  63. Bielskus I, Pfahler NM, Miazga MD, Giovingo M, Knepper PA. Thrombin generation test of TLR4 antagonists compared to conventional anti-platelet drugs. Invest Ophthalmol Vis Sci. ARVO E-abstract 4596, 2017.
  64. Pfahler NM, Bielskus I, Cronin T1, HaneyJ 1, Giovingo MC, Hill J, Patrianakos TP, Volpe NJ, Knepper PA. CD36 Ligand Beta-Amyloid Promotes Coagulation and Inflammation Through Toll-Like Receptor 4.  Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 3721 2018.
  65. Bielskus, I, Pfahler N, Cronin T, Haney  J, Knepper PA. Stop and stabilize β-amyloid: a novel bimodal approach for prevention of β-amyloid aggregation and toxicity. Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 371, 2018.
  66. Knepper PA, Pfahler NM, Bielskus I, Cronin T, Haney J, Giovingo MC,  Patrianakos T,  Pasquale L, Tanna AP, Volpe NJ.  Nailfold Hemorrhages in Primary Open-Angle Glaucoma: Systemic Differences in African American and Caucasian Patients. Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 5078,  2018.
  67. Haney J, Pfahler NM, Bielskus I,, Giovingo MC, Hill J, Cronin T, Volpe N, Knepper PA.  A Flip or Flop: Calcium activated chloride channel in the phosphotidylserine flip: Superactivated platelets and POAG.  Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 5096, 2018.
  68. Cronin T, Pfahler NM, Haney J, Bielskus I, Knepper PA. Amyloid-Beta: A Sticky Conundrum in adult onset macular degeneration. Invest Ophthalmol Vis Sci. ARVO E-meeting abstract 3998, 2018.
  69. Cousins CC, Alosco ML, Cousins HC, Chua A, Steinberg EG, Chapman KR, Hanaan BC, Tripodis Y, Knepper PA, Stern RA, Pasquale LR. Nailfold capillary morphology in Alzheimer’s disease dementia. Alzheimer’s Association International Conference, accepted, 2018.
  70. Knepper PA, Haney J, Pfahler NM, Bielskus I, Giovingo M, Cronin T. The phosphotidylserine flip and its role in super-activated platelets and primary open angle glaucoma. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2018 to 2020, page 329.  Kugler, Amsterdam.
  71. Giovingo M, McCarty RD, Beverley R, Nolan M, Grybauskas A, Burdi RA, Wagner E, Knepper PA. Lipid raft modulation and outflow resistance. In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2018 to 2020, page 324.  Kugler, Amsterdam
  72. Bielskus I,  Dasso L, Pfahler N, Brom C, Aman S,  Zaparackas Z,  Volpe  N, Knepper PA. Macular drusen size and location: the metrics of macular drusen response to curcumin. Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 1213, 2019.
  73. Knepper PA, Pfahler NM, Bielskus I, Giovingo MC, Volpe N. Platelet TLR4 expression in degenerative disease. Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 5166, 2019
  74. Dasso L, Bielskus I, Pfahler NM, Giovingo MC, Volpe NJ, Knepper PA. C-reactive protein potentiates the formation of procoagulant platelets.  Invest Ophthalmol Vis Sci. ARVO  meeting E-abstract 1222, 2019
  75. Giovingo MC, Pfahler NM, Bielskus I, Knepper PA. Toll-like Receptor 4, fibrosis and the trabecular meshwork: A New Prevention. Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 5165, 2019
  76. Pfahler NM, Bielskus I, Giovingo MC, Pasquale LR, Volpe NJ, Knepper PA. Systemic capillary abnormalities in age-related macular degeneration. Invest Ophthalmol Vis Sci. ARVO meeting E-abstract 1199, 2019.
  77. Pfahler NM, Bielskus I, Giovingo MC, Knepper PA On the role of innate immune Toll-like receptor 4 in primary open-angle glaucoma In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2020 to 2022 In Press,  Kugler, Amsterdam
  78. Knepper PA, Pfahler NM, Bielskus I, Giovingo MC,  Volpe NJ. On the prevention and  treatment of progressive visual loss in primary open-angle glaucoma.  In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2020 to 2022 In Press,  Kugler, Amsterdam
  79. Knepper PA, Bielskus I, Pfahler NM, Barry JL, Kakouri A, Giovingo M, Volpe, NJ. Platelet TLR4 activity in neurodegenerative diseases. Invest Ophthalmol Vis Sci. ARVO In Press 2020.
  80. Pfahler NM, Bielskus I, Kakouri A, Barry JL, Giovingo M, Volpe, NJ, Knepper PA. . Platelet complement C3b levels are increased in the dry form of age-related macular degeneration. Invest Ophthalmol Vis Sci. ARVO In Press 2020.
  81. Giovingo M, Pfahler NM, Bielskus I, Kakouri A, Barry JL, Volpe NJ, Knepper PA. Is POAG a systemic microvascular disease? Invest Ophthalmol Vis Sci. ARVO In Press 2020.
  82. Barry JL, Pfahler NM, Kakouri A, Bielskus I, Giovingo M, Aman S, Zaparackas Z, Knepper PA. Curcumin hot spots: a biphasic event in AMD drusen. Invest Ophthalmol Vis Sci. ARVO In Press 2020.
  83. Bielskus I, Kakouri A, Pfahler NM, Barry JL, Aman S, Zaparackas Z, Volpe NJ, Knepper PA. Curcumin acts to regress macular drusen volume in dry AMD. Invest Ophthalmol Vis Sci. ARVO In Press 2020.
  84. Knepper PA, Bielskus IE, Pfahler NM, Kakouri A, Giovingo MC, Volpe N. Microvascular permeability in geographic atrophy; on the role of PLVAP. Invest Ophthalmol Vis Sci. ARVO In Press 2021.
  85. Kakouri A, Pfahler NM, Bielskus IE, Giovingo MC, Aman S, Zaparackas Z, Knepper PA. Slowing the progression of geographic atrophy with oral resveratrol, quercetin, and curcumin. Invest Ophthalmol Vis Sci. ARVO In Press 2021.
  86. Bielskus IE, Pfahler NM, Kakouri A, Aman S, Zaparackas Z, Knepper PA. Can drusen growth in age-related macular degeneration be slowed by oral curcumin? Invest Ophthalmol Vis Sci. ARVO In Press 2021.
  87. Pfahler NM, Bielskus IE, Knepper PA. Systemic complement and innate immune dysregulation in AMD. Invest Ophthalmol Vis Sci. ARVO In Press 2021
  88. Knepper PA, Pfahler NM, Bielskus I, Jordan B, Agni K, Giovingo MC,  Volpe N. Platelet TLR4 expression in degenerative disease.  In: Knepper PA, Samples JR (eds): Glaucoma Research and Clinical Advances: 2020 to 2022 pp 239. Kugler, Amsterdam
  89. Knepper PA, Pfahler NM, Bielskus I, Volpe NJ, Aman S, Zaparackas Z. A Two-Year, Phase 1 Study to Evaluate the Efficacy of Oral Curcumin on Drusen Volume. Invest Ophthalmol Vis Sci. ARVO In Press 2022.
  90. Pfahler NM, Bielskus I, Volpe NJ, Aman S, Zaparackas Z, Knepper PA. Response of Drusen Volume to Curcumin is Correlated with Risk Alleles for Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. ARVO In Press 2022.

Zibute G. Zaparackas, MD

Co-Investigator

Dr. Zibute G. Zaparackas, a pediatric ophthalmologist, is co-investigator of the InSight to Macular Degeneration; The study to treat AMD. Together they have committed their lives to helping everyone from newborns to 100-year-olds stay sighted.  

Their work has been published in highly respected journals and papers and attracted many research grants.

Current Positions

  • Assistant Professor of Ophthalmology
    Northwestern University Feinberg School of Medicine, Chicago, IL

Hospital Staff Appointments

  • Active Attending, 1976-Present
    Children’s Memorial Hospital
  • Attending, 1978 – Present
    Northwestern Memorial Hospital
  • Attending Physician, 1986-1990
    Augustana Hospital

Academic Degrees

  • Pre-Med, 1964-1967
    Wayne State University
  • MD, 1971
    University of Michigan Medical School

Internship

  • Straight Medical, Passavant Hospital, 1971-1972
    Northwestern University

Residency Training

  • Ophthalmology, 1972-1975
    Northwestern University Feinberg School of Medicine
    Chairman: David E. Shoch, MD, PhD
  • Pediatric Ophthalmology, 1974-1975
    Children’s Memorial Hospital
    Division Head: Paul E. Romano, MD

Board Certified

  • American Board of Ophthalmology, 1977

License

  • State of Illinois, 036.045972

Honors

  • Phi Beta Kappa, 1967
  • Best Doctors In America 2005-2014  elected by peers for inclusion in  Best Doctors in America

Academic Appointments

  • Instructor, Department of Ophthalmology, 1978-1980
    Northwestern University Feinberg School of Medicine
  • Associate, Department of Ophthalmology, 1980-1986
    Northwestern University Feinberg School of Medicine
  • Acting Division Chief, Department of Ophthalmology, 1981-1984
    Children’s Memorial Hospital
  • Assistant Professor, Department of Ophthalmology, 1986-Present
    Northwestern University Feinberg School of Medicine

Membership in Societies

  • American Academy of Ophthalmology
  • Chicago Ophthalmological Society
  • American Association of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American Association of Pediatric Ophthalmology and Strabismus
  • Fellow of the Institute of Medicine of Chicago
  • Board of Directors, 1989-1995
    Children’s Memorial Hospital Foundation
  • Medical Center Board of Directors, 1991-1994
    Children’s Memorial Hospital
  • Secretary – Treasurer, 1990-1991
    Vice President, 1991-1992
    President, 1993-1994
    Children’s Memorial Hospital Medical/Dental Staff
  • Board Member, 1998 – Present
    Vice-President, 1997-1998
    Chair of Credentialing Committee, 1998-2017
    Children’s Community Physicians Association
  • Member Admissions Committee , 2011-2017
    Northwestern University, Feinberg School of Medicine 

Articles

  • Koenig, S. B.; Naidich, T. P.; Zaparackas, Z. G.: Optic Gioma Masquerading as Spasmus Nutans. Journal of Pediatric Ophthalmology and Strabismus, 19:20-24, 1982.
  • Naidich, T. P.; McLone, D. G.; Bauer, B. S.; Kernahan, D. A.; Zaparackas, Z. G.: Midline Craniofacial Dysraphism, Midline Cleft Upper Lip, Basal Encephalocele, Callosal Agenesis, and Optic Nerve Dysplasia. (in) American Society for Pediatric Neurosurgery  (ed): Concepts in Pediatric Neurosurgery, Vol 4.  Basel: J Comput Assist Tomography 8:95-102, 1984.
  • Gardner, T. W.; Zaparackas, Z. G.; Naidich, T. P.: Congenital Optic Nerve Colobomas: CT Demonstration. J Comput Assist Tomography 8:95-102, 1984.
  • Tomita, T.; Radkowski, M. A.; Gonzalez-Crussi, F.; Zaparackas, Z.; Flannery, A. M.: Multiple Meningiomas in a Child. Surgical Neurology 29:131-136, Feb. 1988.

Abstracts

  • Knepper, P. A.; Breen, M.; Weinstein, H.; Zaparackas, Z. G.: Bovine Irisciliary Body Glycosaminoglycans. Proc Intern Soc Eye Research 1:68, 1980.
  • Knepper, P. A. and Zaparackas, Z. G.: Glycosaminoglycans and Aqueous Outflow Resistance. Invest Ophthalmol Vis Sci (Suppl) 20:23, 1981.
  • Knepper, P. A.; Zaparackas, Z. G.; McLone, D.G.; Breen, M.; Weinstein, H. G.; Blacik, L.: Glycoconjugates of the Anterior Segment of the Eye. Proc Soc Complex Carbohydrates, No. 50, 1981.
  • Zaparackas, Z. G. and Knepper, P. A.: Chelating Agents and Aqueous Outflow Resistance. Invest Ophthalmol Vis Sci (Suppl) 22:93, 1982.
  • Collins, J.; Zaparackas, Z. G.; Knepper, P.A.: Anterior Segment Complex Carbohydrate Synthesis in Vitro. Invest Ophthalmol Vis Sci (Suppl) 22:31, 1982.
  • Knepper, P. A.; Collins, J.; Zaparackas, Z. G.; Weinstein, H.; Breen, M.: Human Trabecular Meshwork Glycosaminoglycans. Invest Ophthalmol Vis Sci (Suppl) 22:93, 1982.
  • Naidich, T. P.; McLone, D. G.; Bauer, B. S.; Kernahan, D. A.; Zaparackas, Z. G.: Lower Midline Craniofacial Dysraphism: Midline Cleft Upper Lip, Basal Encephalocele, Callosal agenesis and Optic Nerve Dysplasia. AJR 143:695, 1982.
  • Lukas, R.; Wills, J.; Davis, E.; Zaparackas, Z. G.; Mayanil, C. S. K.; and Knepper, P. A.: Transcription Factors are Present in Rabbit Aqueous Fluid. Invest Ophthalmol Vis Sci, 38:S1128, 1997.
  • Knepper, P. A.; Lukas, R.; Goossens, W.; Mayanil, C. S. K.; Zaparackas, Z. G.: Soluble CD44 is Decreased in Primary Open-Angle Glaucoma. Invest Ophthalmol Vis Sci, 39:S705, 1998.
  • Knepper, P. A.; Goossens, W.; Zaparackas, Z.; Wertz, R. D.; Wang, D. O.: Localization of Soluble CD44 in Primary Open-Angle Glaucoma Aqueous Outflow Pathway. Invest Opthalmol Vis Sci, 41:S504, 2000.
  • Bielskus, Indre; Dasso, Lilly; Pfaler, Nicholas M. ; Brom, Clare; Aman, Stephanie; Zaparackas, Zibute; Volpe, Nicholas; Knepper, Paul A. Macular Drusensize and location:  the macular drusen response to curcumin;  ARVO  annual meeting Vancouver, BC  April 2019
  • Presentations
  • Congenital Cataracts, Surgical Grand Rounds, Children’s Memorial Hospital, 1982.
  • Orbital Tumors, Pediatric Surgical Update, Children’s Memorial Hospital, 1982.
  • Ophthalmological Finding in Children with Myelomeningocele, Myelomeningocele Seminar, Children’s Memorial Hospital, 1982.
  • Dissociated Vertical Deviations, Pediatric Ophthalmology Review, University of Illinois, 1982.
  • Ocular Trauma: Diagnosis and therapy, Pediatric Grand Rounds, Columbus Hospital, 1983.
  • Neonatal Emergencies: Can My Baby See?, Pediatric Surgical Update, Children’s Memorial Hospital, 1983.
  • Ocular Findings in Systemic Disease, Pediatric Grand Rounds, Columbus Hospital, 1984.
  • Congenital Cataracts, International Oculoplastic Symposium, Jamaica, 1984.
  • Blunt Trauma and Orbital Fractures, Surgical Grand Rounds, Children’s Memorial Hospital, 1984.
  • Strabismus and Amblyopia: Therapy and Diagnosis, Pediatric Grand Rounds, St. James Hospital, 1984.
  • Acute Ocular Emergencies, Series of Lectures presented to Pediatric Residents, 1981-1984.
  • Ocular Findings in Systemic Disease, Lecture presented to Pediatric Residents, Children’s Memorial Hospital, 1985.
  • New Advances in Congenital Cataract Surgery, Vilnius University, Lithuania, U.S.S.R., 1986.
  • Treatment of Amblyopia and Strabismus, Vilnius University, Lithuania, U.S.S.R., 1986.
  • Ocular Findings in Myelomeningoceles Patients, Myelomeningocele Annual Conference, 1986.
  • Congenital Glaucoma, Pediatric Grand Rounds, Columbus Hospital, 1986.
  • Common Pediatric Ophthalmological Problems in Children with Spina Bifida: Myelomeningocele Annual Conference, May, 1987.
  • Evaluation and Treatment of Pediatric Eye Problems, Pediatric Grand Rounds, Norwegian American Hospital, 1987.
  • Congenital Cataracts and Common Pediatric Eye Problems, Fox River Valley Ophthalmological Conference, 1987.
  • Ophthalmological Disorders Associated with Myelomeningocele, Myelomeningocele Seminar, April, 1988.
  • Congenital Cataracts, University of Vilnius, Lithuania, 1988.
  • Common Pediatric Ophthalmological Problems, University of Vilnius, Lithuania, 1988.
  • Ocular Abnormalities in Children with Myelomeningocele, Myelomeningocele Seminar, 1989.
  • Results of Cataract Surgery in Children with PHPV, Midwest Orthoptic Meeting, May, 1990.
  • Ocular Problems in Children with Brain Tumors, Parent Support Group, Children’s Memorial Hospital, June, 1990.
  • Ocular Complications in Patient’s with Craniofacial Disorders, International Association of Cleft Palate Teams, University of Illinois, December, 1991.
  • New Ocular Therapies for Children with Myelomeningocele, Myelomeningoce Seminar, 1992.
  • Basic Ophthalmology Course for Sophomore Medical Students, Northwestern University Feinberg School of Medicine, 2001.
  • Basic Ophthalmology Course for Sophomore Medical Students, Northwestern University Feinberg School of Medicine, 2002.
  • Common Ocular Problems in Hydrocephalus, International Hydrocephalus Meeting, May, 2002.
  • Pediatric Eye Diseases: CAN TV Hotline 21: August 2003, August 2004, February 2004, August 2006, January 2007, September 2007, January 2008, July 2008.
  • Medical Student Physical Diagnosis Courses: 2006-2019
  • Medical Student Physical Diagnosis Courses 2011-2019
  • Interview Committee, Feinberg School of Medicine 2012-2019

Meetings

  • AAPOS Annual Meeting, April 1999, Toronto, Canada
  • ARVO, May 1999, Fort Lauderdale, Florida
  • AAPOS Annual Meeting, April 2000, San Diego, California
  • ARVO, April 2000, Fort Lauderdale, Florida
  • ISER International Meeting, October 2000, Santa Fe, New Mexico
  • AAPOS Annual Meeting, March 2001, Orlando, Florida
  • ARVO, May 2001, Fort Lauderdale, Florida
  • AAPOS Annual Meeting, March 2002, Seattle, Washington
  • ARVO, May 2002, Fort Lauderdale, Florida
  • ARVO, May 2003, Fort Lauderdale, Florida
  • AAPOS Annual Meeting 2004, Washington, DC
  • ARVO, May 2004, Fort Lauderdale, Florida
  • AAPOS Annual Meeting 2005, Orlando, Florida
  • ARVO, May 2005, Fort Lauderdale, Florida
  • American Academy of Ophthalmology Annual Meeting, November 2004, Chicago, Illinois
  • AAPOS Annual Meeting, February 2006, Keystone, Colorado
  • ARVO, May 2006, Fort Lauderdale, Florida
  • AAPOS Annual Meeting, April 2007, Seattle, Washington
  • ARVO, May 2007, Fort Lauderdale, Florida
  • ISMIE Mutual CME program, April 2007, Chicago, Illinois
  • ARVO, May 2008, Fort Lauderdale, Florida
  • ARVO, May 2009, Fort Lauderdale, Florida
  • ARVO, May 2010, Fort Lauderdale, Florida
  • Trabecular Meshwork Meeting, 2009, San Francisco, California
  • AAPOS Annual Meeting, April 2010, Orlando, Florida
  • American Academy of Ophthalmology Annual Meeting, 2010, Chicago, Illinois
  • Ken Wright Pediatric Ophthalmology Course, November 2010, U of I,  Chicago, IL
  • AAPOS Annual Meeting, March 2011, San Diego, California
  • ARVO, May 2011, Fort Lauderdale, Florida
  • AAPOS Annual Meeting, March 2012, San Antonio, Texas
  • ISER Meeting, July 2012, Berlin, Germany 
  • ARVO, May 2012, Fort Lauderdale, Florida
  • American Academy of Ophthalmology Annual Meeting, 2012, Chicago, Illinois
  • Ken Wright Pediatric Ophthalmology Course, November 2012, U of I, Chicago, IL 
  • AAPOS Annual Meeting, April 2013, Boston, Massachusetts
  • ARVO Annual Meeting, May , 2013, Seattle, Washington
  • AAPOS Annual Meeting, April 2013, Palm Springs, California
  • ARVO Annual Meeting, May 2013, Seattle, Washington
  • AAPOS Annual Meeting, April 2014, Palm Springs, California
  • ARVO Annual Meeting, May 2014, Orlando, Florida
  • AAO Annual Meeting, October 2014, Chicago, Illinois
  • AAPOS Annual Meeting, March 2015, New Orleans, Louisiana
  • ARVO Annual Meeting, May 2015, Denver, Colorado
  • AAO Annual Meeting, November 2015, Las Vegas, Nevada
  • AAPOS Annual Meeting, April 2016, Vancouver, Canada
  • ARVO Annual Meeting, May 2016, Seattle, Washington
  • AAO Annual Meeting, October, 2016, Chicago, Illinois
  • AAPOS Annual Meeting, April 2017, Nashville, Tennessee
  • AAPOS Annual Meeting, March 2018, Washington, DC
  • ARVO Annual Meeting, May 2018, Honolulu, Hawaii
  • AAO Annual Meeting, November 2018, Chicago, Illinois
  • ARVO Annual Meeting, May 2019, Vancouver, BC

What to Expect?

As a part of the Insight to Macular Degeneration Study (IMDS), you will receive a series of exams and study-related treatments. This is a randomized study where you will be given one of two study medication regimens. Both regimens are in pill form.

The study lasts for two years. In that time, you will be required to come into our Chicago office for seven study visits where you will be examined to determine how well you are progressing and a series of questions regarding your state of health. Each study visit includes (at no cost to you): an optical coherence tomography (OCT) retinal scan, visual acuity testing and an interview with the study staff.

You can also expect a twice-daily regimen of the study medication(s).

Step 1

We will call you for an initial screening. During the study you can reach out any time with questions or concerns.

1

Step 2

You will have an initial (in-person) visit which will last approximately 1 hour where we will:

  • Obtain a complete medical history which involves several questions
  • Dilate your pupils
  • Conduct retinal imaging
2

Step 3

You will have subsequent visits which will last approximately 30 minutes where we will:

  • Test visual acuity
  • Conduct retinal imaging, dilation may be required
  • Ask questions about how you’re feeling (any changes or improvements)
  • All study-related treatments will be provided
3

Frequently Asked Questions

A company called Zaparackas and Knepper, Ltd., and RQC Prevention, LLC are funding the study.

You and/or your health-care payer/insurer will not be billed for the costs of the study. Validated parking may be available and a 24-month supply of study medications will be provided at no cost.

You can ask the study doctor or study staff to find out more about costs.

If you decide to be in this study and the study doctor says you can be in the study, your participation will last about 24 months (two years).

You will visit the study center to have the procedures and tests. Ask the study doctor or study staff about your study visit schedule.

If the study doctor or study staff learns any new information that might change your mind about continuing in the study, the study doctor or study staff will tell you about it.

If you experience a change in your health status while participating in the study, please contact the study team to inform them as soon as possible.

You will not receive any payment for your participation in this study.

Your participation in this study is voluntary. You can decide not to be in the study, and you can change your mind about being in the study at any time. If you want to stop being in the study, tell the study doctor or study staff.

The study doctor or study staff or sponsor can remove you from the study at any time, even if you want to stay in the study. This could happen if, for example:

  • The study doctor or study staff believes it is best for you to stop being in the study.
  • You do not follow directions about the study.
  • The sponsor stops the study for any reason.

If you stop being in the study early, the study doctor or study staff may ask you some questions about being in the study. The study doctor or study staff may ask you to participate in some procedures or tests to help you leave the study safely and/or to collect more information for the study.

If you leave the study, the study doctor and study staff will still be able to use your information that they have already collected.

Your identity will be protected as required by law and according to any policies the study center or sponsor may have. Be aware that your study records (which includes your information from your medical records, the videos and photos, your signed and dated consent form, and other information) will be shared as needed for the study. For example, the FDA, the sponsor, and Advarra Review may look at your study and medical records.

All video files and OCT image files will be de-identified (coded). The list that matches the code with your name will be stored separately from the files.

Join the AMD trial

Contact us to join the AMD trial